Circulating RNA signature specific for preeclampsia

A panel of circulating RNA molecules is used to detect pre-eclampsia by identifying specific protein-coding sequences, enhancing early detection and risk assessment, thereby reducing complications.

CN110785499BActive Publication Date: 2024-12-03ILLUMINA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980002993.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-05-15
Filing Date
2019-05-24
Publication Date
2024-12-03
Estimated Expiration
2039-05-24

AI Technical Summary

Technical Problem

Current biomarkers for pre-eclampsia lack discrimination and predictive power for early detection, posing a risk for untreated severe complications in pregnancy.

Method used

Identifying a panel of circulating RNA (C-RNA) molecules, including specific proteins encoded by genes such as ARRDC2, JUN, SKIL, and others, to detect pre-eclampsia through hybridization, PCR, or sequencing, and enriching for protein-coding sequences to assess risk.

Benefits of technology

Provides a robust method for early detection and risk assessment of pre-eclampsia, enabling timely intervention and reducing maternal and fetal complications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002317246250000361
    Figure BDA0002317246250000361
  • Figure BDA0002317246250000371
    Figure BDA0002317246250000371
  • Figure BDA0002317246250000381
    Figure BDA0002317246250000381
Patent Text Reader

Abstract

The present invention includes methods and materials for detecting pre-eclampsia and / or determining an increased risk of pre-eclampsia in a pregnant woman, the method comprising identifying a plurality of circulating RNA (C-RNA) molecules in a biological sample obtained from the pregnant woman.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Continue to apply for data

[0002] This application claims the benefit of U.S. Provisional Application Serial No. 62 / 676,436, filed May 25, 2018, and U.S. Provisional Application Serial No. 62 / 848,219, filed May 15, 2019, the entire contents of each of which are incorporated herein by reference. Technical Field

[0003] The present invention generally relates to methods and materials for the detection and early risk assessment of the pregnancy complication pre-eclampsia. Background Art

[0004] Preeclampsia is a condition that occurs only during pregnancy and affects 5% to 8% of all pregnancies. It is the direct cause of 10%-15% of maternal deaths and 40% of fetal deaths. The three main symptoms of preeclampsia may include high blood pressure that develops after the 20th week of pregnancy, swelling in the hands and feet, and too much protein in the urine (proteinuria). Other signs and symptoms of preeclampsia may include severe headaches, vision changes (including temporary vision loss, blurred vision, or light sensitivity), nausea or vomiting, decreased urine output, low levels of platelets (thrombocytopenia), impaired liver function, and shortness of breath caused by fluid in the lungs.

[0005] The more severe the preeclampsia and the earlier in pregnancy it occurs, the greater the risks to the mother and baby. Preeclampsia may require induction of labor and delivery or delivery by cesarean section. If left untreated, preeclampsia can lead to serious or even fatal complications for the mother and baby. Complications of preeclampsia include fetal growth restriction, low birth weight, premature birth, placental abruption, HELLP syndrome (syndrome of hemolysis, elevated liver enzymes, and low platelet count), eclampsia (a severe form of preeclampsia that causes seizures), organ damage (including damage to the kidneys, liver, lungs, heart, or eyes), and stroke or other brain damage. See, e.g., “Preeclampsia - Symptoms and causes - Mayo Clinic,” April 3, 2018, available on the World Wide Web at mayoclinic.org / diseases-conditions / preeclampsia / symptoms-causes / syc-20355745.

[0006] In the case of early detection and treatment, if pre-eclampsia is detected early and treated with conventional antenatal care, most women can give birth to healthy babies. Although various protein biomarkers show varying levels in maternal serum in the pre-symptomatic stage, these biomarkers lack discrimination and predictive power for individual patients (Karumanchi and Granger, 2016, Hypertension [hypertension]; 67 (2): 238-242). Therefore, identifying biomarkers for early detection of pre-eclampsia is crucial for early diagnosis and treatment of pre-eclampsia. Summary of the invention

[0007] The present invention includes a method of detecting pre-eclampsia and / or determining an increased risk of pre-eclampsia in a pregnant woman, the method comprising:

[0008] identifying a plurality of circulating RNA (C-RNA) molecules in a biological sample obtained from the pregnant woman;

[0009] Wherein the plurality of C-RNA molecules are selected from:

[0010] (a) a plurality of C-RNA molecules encoding at least a portion of a protein, wherein the C-RNA molecules are selected from ARRDC2, JUN, SKIL, ATP13A3, PDE8B, GSTA3, PAPPA2, TIPARP, LEP, RGP1, USP54, CLEC4C, MRPS35, ARHGEF25, CUX2, HEATR9, FSTL3, DDI2, ZMYM6, ST6GALNAC3, GBP2, NES, ETV3, ADAM17 , ATOH8, SLC4A3, TRAF3IP1, TTC21A, HEG1, ASTE1, TMEM108, ENC1, SCAMP1, ARRDC3, SLC26A2, SLIT3, CLIC5, TNFR SF21, PPP1R17, TPST1, GATSL2, SPDYE5, HIPK2, MTRNR2L6, CLCN1, GINS4, CRH, C10orf2, TRUB1, PRG2, ACY3, FAR2, Any one or more, any two or more, any three or more, any four or more, any five or more of CD63, CKAP4, TPCN1, RNF6, THTPA, FOS, PARN, ORAI3, ELMO3, SMPD3, SERPINF1, TMEM11, PSMD11, EBI3, CLEC4M, CCDC151, CPAMD8, CNFN, LILRA4, ADA, C22orf39, PI4KAP1, and ARFGAP3, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, up to all seventy-five; or

[0011] (b) a plurality of C-RNA molecules encoding at least a portion of a protein, wherein the C-RNA molecules are selected from any one or more, any two or more, any one of TIMP4, FLG, HTRA4, AMPH, LCN6, CRH, TEAD4, ARMS2, PAPPA2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, TIMP3, IGFBP5, HSPA12B, CLEC4C, KRT5, PRG2, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, LEP, NES and VSIG4. three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, any twenty-six or more, or all twenty-seven; or

[0012] (c) a plurality of C-RNA molecules encoding at least a portion of a protein, wherein the C-RNA molecules are selected from CYP26B1, IRF6, MYH14, PODXL, PPP1R3C, SH3RF2, TMC7, ZNF366, ADCY1, C6, FAM219A, HAO2, IGIP, IL1R2, NTRK2, SH3PXD2A, SSUH2, SULT2A1, FMO3, FSTL3, GATA5, HTRA1, C8B, H19, MN1, NFE2L1, PRDM16, AP3B2, EMP1, FLNC, STAG3, CPB2, TENC1, RP1L1, A1CF, NPR1, TEK, ERRFI1, ARHGEF15, CD34, RSPO3, ALPK3, SAMD4A, ZCCHC24, LEAP2, MYL2, NRG3, ZBTB16, SERPINA3, AQP7, SRPX, UACA, ANO1, FKBP5, SCN5A, PTPN21, C ACNA1C, ERG, SOX17, WWTR1, AIF1L, CA3, HRG, TAT, AQP7P1, ADRA2C, SYNPO, FN1, GPR116, KRT17, AZGP1, BCL6B, KIF1C, CLIC5, GPR4, GJA5, OLAH, C14orf37 , ZEB1, JAG2, KIF26A, APOLD1, PNMT, MYOM3, PITPNM3, TIMP4, HTRA4, AMPH, LCN6, CRH, TEAD4, ARMS2, PAPPA2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, TIM P3, IGFBP5, HSPA12B, PRG2, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, LEP, NES, VSIG4, HBG2, CADM2, LAMP5, PTGDR2, NOMO1, NXF3, PLD4, BPIFB3, PACSIN 1. any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, up to all one hundred and twenty-two of CUX2, FLG, CLEC4C, and KRT5; or

[0013] (d) a plurality of C-RNA molecules encoding at least a portion of a protein, wherein the C-RNA molecules are selected from any one or more, any two or more, or any three or more of VSIG4, ADAMTS2, NES, FAM107A, LEP, DAAM2, ARHGEF25, TIMP3, PRX, ALOX15B, HSPA12B, IGFBP5, CLEC4C, SLC9A3R2, ADAMTS1, SEMA3G, KRT5, AMPH, PRG2, PAPPA2, TEAD4, CRH, PITPNM3, TIMP4, PNMT, ZEB1, APOLD1, PLD4, CUX2, and HTRA4. any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, any twenty-six or more, any twenty-seven or more, any twenty-eight or more, any twenty-nine or more, or all thirty; or

[0014] (e) a plurality of C-RNA molecules encoding at least a portion of a protein, wherein the C-RNA molecules are selected from any one or more, any two or more of ADAMTS1, ADAMTS2, ALOX15B, AMPH, ARHGEF25, CELF4, DAAM2, FAM107A, HSPA12B, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LEP, LRRC26, NES, OLAH, PACSIN1, PAPPA2, PRX, PTGDR2, SEMA3G, SLC9A3R2, TIMP3 and VSIG4. more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, or all twenty-six; or

[0015] (f) a plurality of C-RNA molecules encoding at least a portion of a protein, wherein the C-RNA molecules are selected from any one or more of ADAMTS1, ADAMTS2, ALOX15B, ARHGEF25, CELF4, DAAM2, FAM107A, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LEP, LRRC26, NES, OLAH, PRX, PTGDR2, SEMA3G, SLC9A3R2, TIMP3 and VSIG4. any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, or all twenty-two; or

[0016] (g) a plurality of C-RNA molecules encoding at least a portion of a protein, wherein the C-RNA molecules are selected from any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, or all eleven (including in some embodiments, seven of ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, PAPPA2, and VSIG4; ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, PAPPA2, and VSIG4; and all eleven of the following: 5, eight of ARRDC2, CLEC4C, LEP, PAPPA2, SKIL, and VSIG4; eight of ADAMTS2, ARHGEF25, ARRDC4, CLEC4C, LEP, NES, SKIL, and VSIG4; ten of ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, CRH, LEP, PAPPA2, SKIL, and VSIG4; six of ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, and SKIL; or eight of ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, LEP, PAPPA2, and SKIL); or

[0017] (h) a plurality of C-RNA molecules encoding at least a portion of a protein, wherein the C-RNA molecules are selected from any one or more, any two or more of LEP, PAPPA2, KCNA5, ADAMTS2, MYOM3, ATP13A3, ARHGEF25, ADA, HTRA4, NES, CRH, ACY3, PLD4, SCT, NOX4, PACSIN1, SERPINF1, SKIL, SEMA3G, TIPARP, LRRC26, PHEX, LILRA4 and PER1. a plurality of, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, or all twenty-four

[0018] This indicates that the pregnant woman has an increased risk of pre-eclampsia and / or pre-eclampsia.

[0019] The present invention includes a method of detecting pre-eclampsia and / or determining an increased risk of pre-eclampsia in a pregnant woman, the method comprising:

[0020] obtaining a biological sample from the pregnant woman;

[0021] purifying a population of circulating RNA (C-RNA) molecules from the biological sample;

[0022] identifying a protein coding sequence encoded by the C-RNA molecule in the purified C-RNA molecule population;

[0023] The protein coding sequence encoded by the C-RNA molecule that encodes at least a portion of a protein is selected from:

[0024] (a) ARRDC2, JUN, SKIL, ATP13A3, PDE8B, GSTA3, PAPPA2, TIPARP, LEP, RGP1, USP54, CLEC4C, MRPS35, ARHGEF25 , CUX2, HEATR9, FSTL3, DDI2, ZMYM6, ST6GALNAC3, GBP2, NES, ETV3, ADAM17, ATOH8, SLC4A3, TRAF3IP1, TTC21A, HEG1, ASTE1, TMEM108, ENC1, SCAMP1, ARRDC3, SLC26A2, SLIT3, CLIC5, TNFRSF21, PPP1R17, TPST1, GATSL2, SP DYE5, HIPK2, MTRNR2L6, CLCN1, GINS4, CRH, C10orf2, TRUB1, PRG2, ACY3, FAR2, CD63, CKAP4, TPCN1, RNF6, THTP A, any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more of FOS, PARN, ORAI3, ELMO3, SMPD3, SERPINF1, TMEM11, PSMD11, EBI3, CLEC4M, CCDC151, CPAMD8, CNFN, LILRA4, ADA, C22orf39, PI4KAP1, and ARFGAP3. any nine or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, any fifty or more, any seventy or more, or all seventy-five; or

[0025] (b) any one or more, any two or more, any three or more, any four or more, any five or more of TIMP4, FLG, HTRA4, AMPH, LCN6, CRH, TEAD4, ARMS2, PAPPA2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, TIMP3, IGFBP5, HSPA12B, CLEC4C, KRT5, PRG2, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, LEP, NES, and VSIG4. any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, any twenty-six or more, or all twenty-seven; or

[0026] (c)CYP26B1, IRF6, MYH14, PODXL, PPP1R3C, SH3RF2, TMC7, ZNF366, ADCY1, C6, FAM219A, HAO2, IGIP, IL1R2, NTRK2, SH3PXD2A, SSUH2, SULT2A1, FMO3, F STL3, GATA5, HTRA1, C8B, H19, MN1, NFE2L1, PRDM16, AP3B2, EMP1, FLNC, STAG3, CPB2, TENC1, RP1L1, A1CF, NPR1, TEK, ERRFI1, ARHGEF15, CD34, RSPO3, A LPK3, SAMD4A, ZCCHC24, LEAP2, MYL2, NRG3, ZBTB16, SERPINA3, AQP7, SRPX, UACA, ANO1, FKBP5, SCN5A, PTPN21, CACNA1C, ERG, SOX17, WWTR1, AIF1L, CA3 , HRG, TAT, AQP7P1, ADRA2C, SYNPO, FN1, GPR116, KRT17, AZGP1, BCL6B, KIF1C, CLIC5, GPR4, GJA5, OLAH, C14orf37, ZEB1, JAG2, KIF26A, APOLD1, PNMT, M Any one or more of YOM3, PITPNM3, TIMP4, HTRA4, AMPH, LCN6, CRH, TEAD4, ARMS2, PAPPA2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, TIMP3, IGFBP5, HSPA12B, PRG2, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, LEP, NES, VSIG4, HBG2, CADM2, LAMP5, PTGDR2, NOMO1, NXF3, PLD4, BPIFB3, PACSIN1, CUX2, FLG, CLEC4C, and KRT5 , any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, any fifty or more, any seventy-five or more, any one hundred or more, or all one hundred and twenty-two; or

[0027] (d) any one or more, any two or more, any three or more, any four or more, or any five or more of VSIG4, ADAMTS2, NES, FAM107A, LEP, DAAM2, ARHGEF25, TIMP3, PRX, ALOX15B, HSPA12B, IGFBP5, CLEC4C, SLC9A3R2, ADAMTS1, SEMA3G, KRT5, AMPH, PRG2, PAPPA2, TEAD4, CRH, PITPNM3, TIMP4, PNMT, ZEB1, APOLD1, PLD4, CUX2, and HTRA4 , any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, any twenty-six or more, any twenty-seven or more, any twenty-eight or more, any twenty-nine or more, or all thirty; or

[0028] (e) any one or more, any two or more, any three or more, any four or more of ADAMTS1, ADAMTS2, ALOX15B, AMPH, ARHGEF25, CELF4, DAAM2, FAM107A, HSPA12B, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LEP, LRRC26, NES, OLAH, PACSIN1, PAPPA2, PRX, PTGDR2, SEMA3G, SLC9A3R2, TIMP3, and VSIG4 a plurality of, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, or all twenty-six; or

[0029] (f) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, or all twenty-two of ADAMTS1, ADAMTS2, ALOX15B, ARHGEF25, CELF4, DAAM2, FAM107A, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LEP, LRRC26, NES, OLAH, PRX, PTGDR2, SEMA3G, SLC9A3R2, TIMP3, and VSIG4; or

[0030] (g) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, or all eleven (including in some embodiments, seven of ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, PAPPA2, and VSIG4; ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, PAPPA2, and VSIG4; or all eleven of CLEC4C, ARHGEF25, ARRDC2, SKIL, PAPPA2, VSIG4, ARRDC4, CRH, and NES. eight of EP, PAPPA2, SKIL, and VSIG4; eight of ADAMTS2, ARHGEF25, ARRDC4, CLEC4C, LEP, NES, SKIL, and VSIG4; ten of ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, CRH, LEP, PAPPA2, SKIL, and VSIG4; six of ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, and SKIL; or eight of ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, LEP, PAPPA2, and SKIL); or

[0031] (h) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, or all twenty-four of LEP, PAPPA2, KCNA5, ADAMTS2, MYOM3, ATP13A3, ARHGEF25, ADA, HTRA4, NES, CRH, ACY3, PLD4, SCT, NOX4, PACSIN1, SERPINF1, SKIL, SEMA3G, TIPARP, LRRC26, PHEX, LILRA4, and PER1.

[0032] This indicates that the pregnant woman has an increased risk of pre-eclampsia and / or pre-eclampsia.

[0033] In some aspects, identifying the protein coding sequence encoded by the C-RNA molecule within the biological sample comprises hybridization, reverse transcriptase PCR, microarray chip analysis, or sequencing.

[0034] In some aspects, identifying a protein coding sequence encoded by a C-RNA molecule within the biological sample comprises sequencing, including, for example, massively parallel sequencing of clonally amplified molecules and / or RNA sequencing.

[0035] In some aspects, the method further comprises removing intact cells from the biological sample; treating the biological sample with a deoxynuclease (DNase) to remove cell-free DNA (cfDNA); synthesizing complementary DNA (cDNA) from C-RNA molecules in the biological sample; and / or enriching the cDNA sequences for protein-encoding DNA sequences by exon enrichment, and then identifying protein-coding sequences encoded by the circulating RNA (C-RNA) molecules.

[0036] The present invention includes a method of detecting pre-eclampsia and / or determining an increased risk of pre-eclampsia in a pregnant woman, the method comprising:

[0037] obtaining a biological sample from the pregnant woman;

[0038] removing intact cells from said biological sample;

[0039] treating the biological sample with deoxynuclease (DNase) to remove cell-free DNA (cfDNA);

[0040] synthesizing complementary DNA (cDNA) from RNA molecules in the biological sample;

[0041] enriching said cDNA sequence for protein-encoding DNA sequences (exon enrichment);

[0042] Sequencing the obtained enriched cDNA sequence; and

[0043] Identifying protein coding sequences encoded by the enriched C-RNA molecules;

[0044] The protein coding sequence encoded by the C-RNA molecule that encodes at least a portion of a protein is selected from:

[0045] (a) ARRDC2, JUN, SKIL, ATP13A3, PDE8B, GSTA3, PAPPA2, TIPARP, LEP, RGP1, USP54, CLEC4C, MRPS35, ARHGEF 25. CUX2, HEATR9, FSTL3, DDI2, ZMYM6, ST6GALNAC3, GBP2, NES, ETV3, ADAM17, ATOH8, SLC4A3, TRAF3IP1, TT C21A, HEG1, ASTE1, TMEM108, ENC1, SCAMP1, ARRDC3, SLC26A2, SLIT3, CLIC5, TNFRSF21, PPP1R17, TPST1, GA TSL2, SPDYE5, HIPK2, MTRNR2L6, CLCN1, GINS4, CRH, C10orf2, TRUB1, PRG2, ACY3, FAR2, CD63, CKAP4, TPCN1, any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, up to all seventy-five of RNF6, THTPA, FOS, PARN, ORAI3, ELMO3, SMPD3, SERPINF1, TMEM11, PSMD11, EBI3, CLEC4M, CCDC151, CPAMD8, CNFN, LILRA4, ADA, C22orf39, PI4KAP1, and ARFGAP3; or

[0046] (b) any one or more, any two or more, any three or more, any four or more of TIMP4, FLG, HTRA4, AMPH, LCN6, CRH, TEAD4, ARMS2, PAPPA2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, TIMP3, IGFBP5, HSPA12B, CLEC4C, KRT5, PRG2, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, LEP, NES, and VSIG4, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, any twenty-six or more, or all twenty-seven; or

[0047] (c)CYP26B1, IRF6, MYH14, PODXL, PPP1R3C, SH3RF2, TMC7, ZNF366, ADCY1, C6, FAM219A, HAO2, IGIP, IL1R2, NTRK2, SH3PXD2A, SSUH2, SULT2A1, FMO 3. FSTL3, GATA5, HTRA1, C8B, H19, MN1, NFE2L1, PRDM16, AP3B2, EMP1, FLNC, STAG3, CPB2, TENC1, RP1L1, A1CF, NPR1, TEK, ERRFI1, ARHGEF15, CD34, R SPO3, ALPK3, SAMD4A, ZCCHC24, LEAP2, MYL2, NRG3, ZBTB16, SERPINA3, AQP7, SRPX, UACA, ANO1, FKBP5, SCN5A, PTPN21, CACNA1C, ERG, SOX17, WWTR1, AIF1L, CA3, HRG, TAT, AQP7P1, ADRA2C, SYNPO, FN1, GPR116, KRT17, AZGP1, BCL6B, KIF1C, CLIC5, GPR4, GJA5, OLAH, C14orf37, ZEB1, JAG2, KIF26A, A POLD1, PNMT, MYOM3, PITPNM3, TIMP4, HTRA4, AMPH, LCN6, CRH, TEAD4, ARMS2, PAPPA2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, TIMP3, IGFBP5, HSPA12 B. PRG2, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, LEP, NES, VSIG4, HBG2, CADM2, LAMP5, PTGDR2, NOMO1, NXF3, PLD4, BPIFB3, PACSIN1, CUX2, FLG, C any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, up to all one hundred and twenty-two of LEC4C and KRT5; or

[0048] (d) any one or more, any two or more, any three or more, any four or more, or any five or more of VSIG4, ADAMTS2, NES, FAM107A, LEP, DAAM2, ARHGEF25, TIMP3, PRX, ALOX15B, HSPA12B, IGFBP5, CLEC4C, SLC9A3R2, ADAMTS1, SEMA3G, KRT5, AMPH, PRG2, PAPPA2, TEAD4, CRH, PITPNM3, TIMP4, PNMT, ZEB1, APOLD1, PLD4, CUX2, and HTRA4 , any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, any twenty-six or more, any twenty-seven or more, any twenty-eight or more, any twenty-nine or more, or all thirty; or

[0049] (e) any one or more, any two or more, any three or more, any four or more of ADAMTS1, ADAMTS2, ALOX15B, AMPH, ARHGEF25, CELF4, DAAM2, FAM107A, HSPA12B, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LEP, LRRC26, NES, OLAH, PACSIN1, PAPPA2, PRX, PTGDR2, SEMA3G, SLC9A3R2, TIMP3, and VSIG4 a plurality of, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, or all twenty-six; or

[0050] (f) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, or all twenty-two of ADAMTS1, ADAMTS2, ALOX15B, ARHGEF25, CELF4, DAAM2, FAM107A, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LEP, LRRC26, NES, OLAH, PRX, PTGDR2, SEMA3G, SLC9A3R2, TIMP3, and VSIG4; or

[0051] (g) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, or all eleven (including in some embodiments, seven of ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, PAPPA2, and VSIG4; ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, PAPPA2, and VSIG4; or all eleven of CLEC4C, ARHGEF25, ARRDC2, SKIL, PAPPA2, VSIG4, ARRDC4, CRH, and NES. eight of EP, PAPPA2, SKIL, and VSIG4; eight of ADAMTS2, ARHGEF25, ARRDC4, CLEC4C, LEP, NES, SKIL, and VSIG4; ten of ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, CRH, LEP, PAPPA2, SKIL, and VSIG4; six of ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, and SKIL; or eight of ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, LEP, PAPPA2, and SKIL); or

[0052] (h) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, or all twenty-four of LEP, PAPPA2, KCNA5, ADAMTS2, MYOM3, ATP13A3, ARHGEF25, ADA, HTRA4, NES, CRH, ACY3, PLD4, SCT, NOX4, PACSIN1, SERPINF1, SKIL, SEMA3G, TIPARP, LRRC26, PHEX, LILRA4, and PER1.

[0053] This indicates that the pregnant woman has an increased risk of pre-eclampsia and / or pre-eclampsia.

[0054] The present invention includes a method for identifying a circulating RNA marker associated with an increased risk of pre-eclampsia, the method comprising obtaining a biological sample from a pregnant woman; removing intact cells from the biological sample; treating the biological sample with a deoxynuclease (DNase) to remove cell-free DNA (cfDNA); synthesizing complementary DNA (cDNA) from RNA molecules in the biological sample; enriching the cDNA sequences for protein-encoding DNA sequences (exon enrichment); sequencing the resulting enriched cDNA sequences; and identifying protein-encoding sequences encoded by the enriched C-RNA molecules.

[0055] The present invention comprises a method comprising:

[0056] obtaining a biological sample from the pregnant woman;

[0057] removing intact cells from said biological sample;

[0058] treating the biological sample with deoxynuclease (DNase) to remove cell-free DNA (cfDNA);

[0059] synthesizing complementary DNA (cDNA) from RNA molecules in the biological sample;

[0060] enriching said cDNA sequence for protein-encoding DNA sequences (exon enrichment);

[0061] Sequencing the obtained enriched cDNA sequence; and

[0062] identifying protein coding sequences encoded by the enriched C-RNA molecules;

[0063] Wherein the protein coding sequence comprises at least a portion of a protein selected from:

[0064] (a) ARRDC2, JUN, SKIL, ATP13A3, PDE8B, GSTA3, PAPPA2, TIPARP, LEP, RGP1, USP54, CLEC4C, MRPS35, ARHGE F25, CUX2, HEATR9, FSTL3, DDI2, ZMYM6, ST6GALNAC3, GBP2, NES, ETV3, ADAM17, ATOH8, SLC4A3, TRAF3IP1, T TC21A, HEG1, ASTE1, TMEM108, ENC1, SCAMP1, ARRDC3, SLC26A2, SLIT3, CLIC5, TNFRSF21, PPP1R17, TPST1, G ATSL2, SPDYE5, HIPK2, MTRNR2L6, CLCN1, GINS4, CRH, C10orf2, TRUB1, PRG2, ACY3, FAR2, CD63, CKAP4, TPCN 1, any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five, up to all seventy-five of RNF6, THTPA, FOS, PARN, ORAI3, ELMO3, SMPD3, SERPINF1, TMEM11, PSMD11, EBI3, CLEC4M, CCDC151, CPAMD8, CNFN, LILRA4, ADA, C22orf39, PI4KAP1, and ARFGAP3; or

[0065] (b) any one or more, any two or more, any three or more, any four or more, any five or more of TIMP4, FLG, HTRA4, AMPH, LCN6, CRH, TEAD4, ARMS2, PAPPA2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, TIMP3, IGFBP5, HSPA12B, CLEC4C, KRT5, PRG2, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, LEP, NES, and VSIG4. any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, any twenty-six or more, or all twenty-seven; or

[0066] (c)CYP26B1, IRF6, MYH14, PODXL, PPP1R3C, SH3RF2, TMC7, ZNF366, ADCY1, C6, FAM219A, HAO2, IGIP, IL1R2, NTRK2, SH3PXD2A, SSUH2, SULT2A1, FMO 3. FSTL3, GATA5, HTRA1, C8B, H19, MN1, NFE2L1, PRDM16, AP3B2, EMP1, FLNC, STAG3, CPB2, TENC1, RP1L1, A1CF, NPR1, TEK, ERRFI1, ARHGEF15, CD34, RSPO3, ALPK3, SAMD4A, ZCCHC24, LEAP2, MYL2, NRG3, ZBTB16, SERPINA3, AQP7, SRPX, UACA, ANO1, FKBP5, SCN5A, PTPN21, CACNA1C, ERG, SOX17, WWTR 1. AIF1L, CA3, HRG, TAT, AQP7P1, ADRA2C, SYNPO, FN1, GPR116, KRT17, AZGP1, BCL6B, KIF1C, CLIC5, GPR4, GJA5, OLAH, C14orf37, ZEB1, JAG2, KIF26A , APOLD1, PNMT, MYOM3, PITPNM3, TIMP4, HTRA4, AMPH, LCN6, CRH, TEAD4, ARMS2, PAPPA2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, TIMP3, IGFBP5, HSP A12B, PRG2, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, LEP, NES, VSIG4, HBG2, CADM2, LAMP5, PTGDR2, NOMO1, NXF3, PLD4, BPIFB3, PACSIN1, CUX2, FL G, any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, up to all one hundred and twenty-two; or

[0067] (d) any one or more, any two or more, any three or more, any four or more, or any five or more of VSIG4, ADAMTS2, NES, FAM107A, LEP, DAAM2, ARHGEF25, TIMP3, PRX, ALOX15B, HSPA12B, IGFBP5, CLEC4C, SLC9A3R2, ADAMTS1, SEMA3G, KRT5, AMPH, PRG2, PAPPA2, TEAD4, CRH, PITPNM3, TIMP4, PNMT, ZEB1, APOLD1, PLD4, CUX2, and HTRA4 , any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, any twenty-six or more, any twenty-seven or more, any twenty-eight or more, any twenty-nine or more, or all thirty; or

[0068] (e) any one or more, any two or more, any three or more, any four or more of ADAMTS1, ADAMTS2, ALOX15B, AMPH, ARHGEF25, CELF4, DAAM2, FAM107A, HSPA12B, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LEP, LRRC26, NES, OLAH, PACSIN1, PAPPA2, PRX, PTGDR2, SEMA3G, SLC9A3R2, TIMP3, and VSIG4 a plurality of, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, or all twenty-six; or

[0069] (f) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, or all twenty-two of ADAMTS1, ADAMTS2, ALOX15B, ARHGEF25, CELF4, DAAM2, FAM107A, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LEP, LRRC26, NES, OLAH, PRX, PTGDR2, SEMA3G, SLC9A3R2, TIMP3, and VSIG4; or

[0070] (g) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, or all eleven (including in some embodiments, seven of ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, PAPPA2, and VSIG4; ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, PAPPA2, and VSIG4; or all eleven of CLEC4C, ARHGEF25, ARRDC2, SKIL, PAPPA2, VSIG4, ARRDC4, CRH, and NES. eight of EP, PAPPA2, SKIL, and VSIG4; eight of ADAMTS2, ARHGEF25, ARRDC4, CLEC4C, LEP, NES, SKIL, and VSIG4; ten of ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, CRH, LEP, PAPPA2, SKIL, and VSIG4; six of ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, and SKIL; or eight of ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, LEP, PAPPA2, and SKIL); or

[0071] (h) any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, or all twenty-four of LEP, PAPPA2, KCNA5, ADAMTS2, MYOM3, ATP13A3, ARHGEF25, ADA, HTRA4, NES, CRH, ACY3, PLD4, SCT, NOX4, PACSIN1, SERPINF1, SKIL, SEMA3G, TIPARP, LRRC26, PHEX, LILRA4, and PER1.

[0072] In some aspects, the biological sample comprises plasma.

[0073] In some aspects, the biological sample is obtained from a pregnant woman at less than 16 weeks gestation or less than 20 weeks gestation.

[0074] In some aspects, the biological sample is obtained from a pregnant woman who is greater than 20 weeks gestation.

[0075] The present invention includes a circulating RNA (C-RNA) signature with increased risk of preeclampsia, wherein the C-RNA signature encodes ARRDC2, JUN, SKIL, ATP13A3, PDE8B, GSTA3, PAPPA2, TIPARP, LEP, RGP1, USP54, CLEC4C, MRPS35, ARHGEF25, CUX2, HEATR9, FSTL3, DDI2, ZMYM6, ST6GALNAC3, GBP2, NES, ETV3, ADAM17, A TOH8, SLC4A3, TRAF3IP1, TTC21A, HEG1, ASTE1, TMEM108, ENC1, SCAMP1, ARRDC3, SLC26A2, SLIT3, CLIC5, TNFRSF21, P PP1R17, TPST1, GATSL2, SPDYE5, HIPK2, MTRNR2L6, CLCN1, GINS4, CRH, C10orf2, TRUB1, PRG2, ACY3, FAR2, CD63, CKAP 4. any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more of TPCN1, RNF6, THTPA, FOS, PARN, ORAI3, ELMO3, SMPD3, SERPINF1, TMEM11, PSMD11, EBI3, CLEC4M, CCDC151, CPAMD8, CNFN, LILRA4, ADA, C22orf39, PI4KAP1, and ARFGAP3, Any eight or more, any nine or more, any ten or more, any eleven or more, any twelve, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, more than fifty or more, any seventy or more, up to at least a portion of all seventy-five.

[0076] The present invention includes a circulating RNA (C-RNA) marker with increased risk of preeclampsia, wherein the C-RNA marker encodes any one or more, any two or more, any one of TIMP4, FLG, HTRA4, AMPH, LCN6, CRH, TEAD4, ARMS2, PAPPA2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, TIMP3, IGFBP5, HSPA12B, CLEC4C, KRT5, PRG2, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, LEP, NES and VSIG4. Three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, any twenty-six or more, or at least a portion of all twenty-seven.

[0077] The present invention includes a circulating RNA (C-RNA) signature for increased risk of preeclampsia, wherein the C-RNA signature encodes CYP26B1, IRF6, MYH14, PODXL, PPP1R3C, SH3RF2, TMC7, ZNF366, ADCY1, C6, FAM219A, HAO2, IGIP, IL1R2, NTRK2, SH3PXD2A, SSUH2, SULT2A1, FMO3, FSTL3, GATA5, HTRA1, C8B, H19, MN1, NFE2 L1, PRDM16, AP3B2, EMP1, FLNC, STAG3, CPB2, TENC1, RP1L1, A1CF, NPR1, TEK, ERRFI1, ARHGEF15, CD34, RSPO3, ALPK3, S AMD4A, ZCCHC24, LEAP2, MYL2, NRG3, ZBTB16, SERPINA3, AQP7, SRPX, UACA, ANO1, FKBP5, SCN5A, PTPN21, CACNA1C, ERG, S OX17, WWTR1, AIF1L, CA3, HRG, TAT, AQP7P1, ADRA2C, SYNPO, FN1, GPR116, KRT17, AZGP1, BCL6B, KIF1C, CLIC5, GPR4, GJ A5, OLAH, C14orf37, ZEB1, JAG2, KIF26A, APOLD1, PNMT, MYOM3, PITPNM3, TIMP4, HTRA4, AMPH, LCN6, CRH, TEAD4, ARMS2, at least a portion of PAPPA2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, TIMP3, IGFBP5, HSPA12B, PRG2, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, LEP, NES, VSIG4, HBG2, CADM2, LAMP5, PTGDR2, NOMO1, NXF3, PLD4, BPIFB3, PACSIN1, CUX2, FLG, CLEC4C, and KRT5.

[0078] The present invention includes a circulating RNA (C-RNA) marker with increased risk of preeclampsia, wherein the C-RNA marker encodes any one or more, any two or more, or any three or more of VSIG4, ADAMTS2, NES, FAM107A, LEP, DAAM2, ARHGEF25, TIMP3, PRX, ALOX15B, HSPA12B, IGFBP5, CLEC4C, SLC9A3R2, ADAMTS1, SEMA3G, KRT5, AMPH, PRG2, PAPPA2, TEAD4, CRH, PITPNM3, TIMP4, PNMT, ZEB1, APOLD1, PLD4, CUX2, and HTRA4. any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, any twenty-four or more, any twenty-five or more, any twenty-six or more, any twenty-seven or more, any twenty-eight or more, any twenty-nine or more, or at least a portion of all thirty.

[0079] The present invention includes a circulating RNA (C-RNA) marker for increased risk of preeclampsia, wherein the C-RNA marker encodes any one or more, any two or more of ADAMTS1, ADAMTS2, ALOX15B, AMPH, ARHGEF25, CELF4, DAAM2, FAM107A, HSPA12B, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LEP, LRRC26, NES, OLAH, PACSIN1, PAPPA2, PRX, PTGDR2, SEMA3G, SLC9A3R2, TIMP3 and VSIG4. More kinds, any three or more kinds, any four or more kinds, any five or more kinds, any six or more kinds, any seven or more kinds, any eight or more kinds, any nine or more kinds, any ten or more kinds, any eleven or more kinds, any twelve or more kinds, any thirteen or more kinds, any fourteen or more kinds, any fifteen or more kinds, any sixteen or more kinds, any seventeen or more kinds, any eighteen or more kinds, any nineteen or more kinds, any twenty or more kinds, any twenty-one or more kinds, any twenty-two or more kinds, any twenty-three or more kinds, any twenty-four or more kinds, any twenty-five or more kinds, or at least a portion of all twenty-six kinds.

[0080] The present invention includes a circulating RNA (C-RNA) marker with increased risk of preeclampsia, wherein the C-RNA marker encodes any one or more of ADAMTS1, ADAMTS2, ALOX15B, ARHGEF25, CELF4, DAAM2, FAM107A, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LEP, LRRC26, NES, OLAH, PRX, PTGDR2, SEMA3G, SLC9A3R2, TIMP3 and VSIG4. any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, or at least a portion of all twenty-two.

[0081] The present invention includes a circulating RNA (C-RNA) signature that increases the risk of pre-eclampsia, the C-RNA signature encoding at least a portion of any one or more, any two or more, any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, or all eleven of CLEC4C, ARHGEF25, ADAMTS2, LEP, ARRDC2, SKIL, PAPPA2, VSIG4, ARRDC4, CRH, and NES, including in some embodiments, seven of ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, PAPPA2, and VSIG4; eight of RHGEF25, ARRDC2, CLEC4C, LEP, PAPPA2, SKIL, and VSIG4; eight of ADAMTS2, ARHGEF25, ARRDC4, CLEC4C, LEP, NES, SKIL, and VSIG4; ten of ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, CRH, LEP, PAPPA2, SKIL, and VSIG4; six of ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, and SKIL; or eight of ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, LEP, PAPPA2, and SKIL.

[0082] The present invention includes a circulating RNA (C-RNA) marker with increased risk of preeclampsia, wherein the C-RNA marker encodes any one or more, any two or more of LEP, PAPPA2, KCNA5, ADAMTS2, MYOM3, ATP13A3, ARHGEF25, ADA, HTRA4, NES, CRH, ACY3, PLD4, SCT, NOX4, PACSIN1, SERPINF1, SKIL, SEMA3G, TIPARP, LRRC26, PHEX, LILRA4 and PER1 any three or more, any four or more, any five or more, any six or more, any seven or more, any eight or more, any nine or more, any ten or more, any eleven or more, any twelve or more, any thirteen or more, any fourteen or more, any fifteen or more, any sixteen or more, any seventeen or more, any eighteen or more, any nineteen or more, any twenty or more, any twenty-one or more, any twenty-two or more, any twenty-three or more, or at least a portion of all twenty-four.

[0083] The present invention includes a solid support array comprising a plurality of agents capable of binding and / or identifying a C-RNA marker as described herein.

[0084] The present invention includes a kit comprising a plurality of probes capable of binding and / or identifying a C-RNA marker as described herein.

[0085] The present invention includes a kit comprising a plurality of primers for selectively amplifying a C-RNA marker as described herein.

[0086] As used herein, the term "nucleic acid" is intended to be consistent with its use in the art, and includes naturally occurring nucleic acids or functional analogs thereof. Particularly useful functional analogs can hybridize with nucleic acids in a sequence-specific manner, or can be used as a template for replicating a specific nucleotide sequence. Naturally occurring nucleic acids generally have a backbone containing a phosphodiester bond. The analog structure may have an alternative backbone connection, which includes any of the various backbone connections known in the art. Naturally occurring nucleic acids generally have deoxyribose (e.g., found in deoxyribonucleic acid (DNA)) or ribose (e.g., found in ribonucleic acid (RNA)). Nucleic acids may contain any of a variety of analogs of these sugar moieties known in the art. Nucleic acids may include natural or non-natural bases. In this regard, natural deoxyribonucleic acids may have one or more bases selected from the group consisting of adenine, thymine, cytosine or guanine, and ribonucleic acids may have one or more bases selected from the group consisting of uracil, adenine, cytosine or guanine. Useful non-natural bases that may be included in nucleic acids are known in the art. When used in reference to nucleic acids, the terms "template" and "target" in the context of the methods or compositions described herein are intended as semantic identifiers for nucleic acids and do not necessarily limit the structure or function of the nucleic acids unless otherwise expressly stated.

[0087] As used herein, "amplify, amplifying" or "amplification reaction" and its derivatives generally refer to any action or process in which at least a portion of a nucleic acid molecule is replicated or copied into at least another nucleic acid molecule. The additional nucleic acid molecule optionally includes a sequence that is substantially identical or substantially complementary to at least some portions of the target nucleic acid molecule. The target nucleic acid molecule can be single-stranded or double-stranded, and the additional nucleic acid molecule can be independently single-stranded or double-stranded. Amplification optionally includes linear or exponential replication of nucleic acid molecules. In some embodiments, such amplification can be performed using isothermal conditions; in other embodiments, such amplification can include thermal cycling. In some embodiments, amplification is a multiplex amplification, which includes amplifying multiple target sequences simultaneously in a single amplification reaction. In some embodiments, "amplification" includes amplifying at least some portions of DNA- and RNA-based nucleic acids, either individually or in combination. The amplification reaction may include any amplification method known to those of ordinary skill in the art. In some embodiments, the amplification reaction includes a polymerase chain reaction (PCR).

[0088] As used herein, "amplification conditions" and their derivatives generally refer to conditions suitable for amplifying one or more nucleic acid sequences. Such amplification can be linear or exponential. In some embodiments, the amplification conditions may include isothermal conditions or may alternatively include thermal cycling conditions, or a combination of isothermal and thermal cycling conditions. In some embodiments, conditions suitable for amplifying one or more nucleic acid sequences include polymerase chain reaction (PCR) conditions. Generally, amplification conditions refer to a reaction mixture sufficient to amplify nucleic acids, such as one or more target sequences, or to amplify amplified target sequences connected to one or more adapters (e.g., amplified target sequences connected to adapters). Generally, amplification conditions include a catalyst for amplification or for nucleic acid synthesis, such as a polymerase; a primer having a certain degree of complementarity with the nucleic acid to be amplified; and nucleotides, such as deoxyribonucleotide triphosphates (dNTPs), which, once hybridized with nucleic acids, can promote the extension of primers. Amplification conditions may require hybridization or annealing of primers to nucleic acids, primer extension, and denaturation steps, in which the extended primers are separated from the nucleic acid sequences being amplified. Generally, but not necessarily, amplification conditions may include thermal cycling; in some embodiments, amplification conditions include multiple cycles in which annealing, extension, and separation steps are repeated. Typically, amplification conditions include cations such as Mg ++ or Mn ++ , and may also include modifiers of various ionic strengths.

[0089] As used herein, the term "polymerase chain reaction" (PCR) refers to the method of U.S. Patent Nos. 4,683,195 and 4,683,202 of KBMullis, which describes a method of increasing the concentration of a target polynucleotide segment in a genomic DNA mixture without cloning or purification. The method for amplifying a target polynucleotide consists of the following: an excess of two oligonucleotide primers are introduced into a DNA mixture containing the desired target polynucleotide, and then a series of thermal cycles are performed in the presence of a DNA polymerase. The two primers are complementary to the respective chains of their target double-stranded polynucleotides. First, the mixture is denatured at a higher temperature, and then the primers are annealed to the complementary sequences in the target polynucleotide molecules. After annealing, the primers are extended with a polymerase to form a pair of new complementary chains. The steps of denaturation, primer annealing and polymerase extension can be repeated multiple times (referred to as thermal cycles) to obtain a high concentration of amplified segments of the desired target polynucleotides. The length of the amplified segments (amplicons) of the desired target polynucleotides is determined by the relative positions of the primers relative to each other, and therefore, the length is a controllable parameter. By repeating this process, the method is called "polymerase chain reaction" (hereinafter referred to as "PCR"). Since the desired amplified segment of the target polynucleotide becomes the main nucleic acid sequence in the mixture (in terms of concentration), it is called "PCR amplification". In an improvement to the above method, the target nucleic acid molecule can be PCR amplified using multiple different primer pairs, in some cases, one or more primer pairs for each target nucleic acid molecule of interest, thereby forming a multiplex PCR reaction.

[0090] As used herein, the term "primer" and its derivatives generally refer to any polynucleotide that can hybridize with a target sequence of interest. Typically, a primer acts as a substrate on which nucleotides can be polymerized by a polymerase; however, in some embodiments, a primer can be incorporated into a synthetic nucleic acid chain and provide a site to which another primer can hybridize to initiate the synthesis of a new chain complementary to the synthetic nucleic acid molecule. A primer can include any combination of nucleotides or their analogs. In some embodiments, a primer is a single-stranded oligonucleotide or polynucleotide. The terms "polynucleotide" and "oligonucleotide" are used interchangeably herein to refer to a polymeric form of nucleotides of any length, and can include ribonucleotides, deoxyribonucleotides, their analogs, or mixtures thereof. These terms should be understood to include analogs of DNA or RNA made of nucleotide analogs as equivalents, and are applicable to single-stranded (e.g., sense or antisense) and double-stranded polynucleotides. The term used herein also encompasses cDNA, which is a complementary or copied DNA produced from an RNA template, for example, by the action of a reverse transcriptase. The term refers only to the primary structure of the molecule. Thus, the term includes triple-, double-, and single-stranded deoxyribonucleic acid ("DNA"), and triple-, double-, and single-stranded ribonucleic acid ("RNA").

[0091] As used herein, the terms "library" and "sequencing library" refer to a collection or a plurality of template molecules that share a common sequence at their 5' end and a common sequence at their 3' end. A collection of template molecules containing a known common sequence at their 3' and 5' ends may also be referred to as a 3' and 5' modified library.

[0092] As used herein, the term "flow cell" refers to a chamber comprising a solid surface through which one or more fluid reagents can flow. Examples of flow cells and associated fluid systems and detection platforms that can be easily used in the methods of this disclosure are described in, for example, Bentley et al., Nature [Nature] 456:53-59 (2008), WO 04 / 018497; US 7,057,026; WO 91 / 06678; WO 07 / 123744; US 7,329,492; US 7,211,414; US 7,315,019; US 7,405,281 and US 2008 / 0108082.

[0093] As used herein, the term "amplicon" means the product of a copy nucleic acid when used for nucleic acid, wherein the product has a nucleotide sequence identical or complementary to at least a portion of the nucleotide sequence of the nucleic acid. An amplicon can be produced by any of a variety of amplification methods using the nucleic acid or its amplicon as a template, including, for example, PCR, rolling circle amplification (RCA), connection extension or connection chain reaction. An amplicon can be a nucleic acid molecule with a specific nucleotide sequence (for example, a PCR product) of a single copy or a nucleotide sequence (for example, a concatemer product of RCA) of multiple copies. The first amplicon of a target nucleic acid is typically a complementary copy. Subsequent amplicon is a copy produced from a target nucleic acid or a first amplicon after producing the first amplicon. Subsequent amplicon can have a sequence that is substantially complementary to the target nucleic acid or substantially identical to the target nucleic acid.

[0094] As used herein, the term "array" refers to a site population that can be distinguished from each other according to relative position. Different molecules located at different sites of the array can be distinguished from each other according to the position of the site in the array. A single site of an array may include one or more molecules of a specific type. For example, a site may include a single target nucleic acid molecule with a specific sequence, or a site may include several nucleic acid molecules with the same sequence (and / or its complementary sequence). The sites of an array may be different features located on the same substrate. Exemplary features include, but are not limited to, holes in a substrate, beads (or other particles) in or on a substrate, projections of a substrate, ridges on a substrate, or channels in a substrate. The sites of an array may be separate substrates each with different molecules. Different molecules attached to a separate substrate may be identified according to the position of the substrate on a surface associated with the substrate, or according to the position of the substrate in a liquid or gel. Exemplary arrays in which separate substrates are located on the surface include, but are not limited to, those with beads in holes.

[0095] The term "next generation sequencing (NGS)" herein refers to sequencing methods that allow for massively parallel sequencing of clonally amplified molecules and single nucleic acid molecules. Non-limiting examples of NGS include synthesis sequencing using reversible dye terminators and ligation sequencing.

[0096] As used herein, the term "sensitivity" is equal to the number of true positives divided by the sum of true positives and false negatives.

[0097] As used herein, the term "specificity" is equal to the number of true negatives divided by the sum of true negatives and false positives.

[0098] The term "enrichment" herein refers to the process of amplifying nucleic acids contained in a portion of a sample. Enrichment includes specific enrichment targeting a specific sequence (eg, a polymorphic sequence), and non-specific enrichment of the entire genome of amplified DNA fragments of the sample.

[0099] As used herein, the term "each," when applied to a collection of items, is intended to identify a single item in the collection, but not necessarily every item in the collection unless the context clearly indicates otherwise.

[0100] As used herein, "providing" in the context of a composition, article, nucleic acid or core means making the composition, article, nucleic acid or core, purchasing the composition, article, nucleic acid or core, or otherwise obtaining the compound, composition, article or core.

[0101] The term "and / or" means one or all of the listed elements or any combination of two or more of the listed elements.

[0102] The words "preferred" and "preferably" refer to embodiments of the present disclosure that may provide certain benefits in certain circumstances. However, other embodiments may also be preferred under the same or other circumstances. In addition, the description of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the present disclosure.

[0103] The terms "comprises" and variations thereof do not have a limiting meaning where these terms appear in the description and claims.

[0104] It should be understood that when the language "include", "includes", or "including" etc. is used herein to describe an embodiment, other similar embodiments described in terms of "consisting of" and / or "consisting essentially of" are also provided.

[0105] Unless otherwise specified, "a", "an", "the", and "at least one" are used interchangeably and mean one or more than one.

[0106] Also herein, the recitations of numerical ranges by endpoints include all numbers subsumed within that range (eg, 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).

[0107] Throughout the specification, references to "one embodiment," "an embodiment," "certain embodiments," or "some embodiments," etc., mean that a particular feature, configuration, composition, or characteristic described in conjunction with that embodiment is included in at least one embodiment of the present disclosure. Thus, the appearances of these phrases in various places throughout the specification are not necessarily referring to the same embodiment of the present disclosure. Furthermore, the particular features, configurations, compositions, or characteristics may be combined in any suitable manner in one or more embodiments.

[0108] For any method disclosed herein that includes discrete steps, the steps may be performed in any practicable order. Also, any combination of two or more steps may be performed simultaneously, if appropriate.

[0109] The above summary of the present disclosure is not intended to describe each disclosed embodiment or each implementation of the present disclosure. The following description more specifically illustrates illustrative embodiments. In several places throughout the application, guidance is provided by lists of examples, which can be used in various combinations. In each case, the lists are used only as representative groups and should not be interpreted as exclusive lists. BRIEF DESCRIPTION OF THE DRAWINGS

[0110] Figure 1 .Schematic representation of the relationship between placental health, maternal response, and fetal response.

[0111] Figure 2 .The origin of circular RNA (C-RNA).

[0112] Figure 3 Library preparation workflow for .C-RNA.

[0113] Figure 4 . Validation of the C-RNA method comparing late pregnancy and non-pregnant samples.

[0114] Figure 5 . Validation of the C-RNA method using longitudinal pregnancy samples.

[0115] Figure 6 . Description of clinical studies.

[0116] Figure 7 .Characteristics of sequencing data.

[0117] Figure 8 . Relying on the entire dataset to classify PE without selecting any gene.

[0118] Fig. 9 .Description of the bootstrap method.

[0119] Fig.10 .Classification of pre-eclampsia samples using the bootstrap method.

[0120] Fig.11 .Detection of overabundant preeclampsia genes.

[0121] Fig.12 .Standard Adaboost model.

[0122] Fig.13 . Independent cohorts allowed further validation of preeclampsia markers.

[0123] Fig.14 .Performance of the standard adaboost model in classification of pre-eclampsia.

[0124] Fig.15 .Classification of pre-eclampsia using the standard DEX TREAT analysis.

[0125] Fig.16 .Genetic selection and classification of preeclampsia using the jackknife approach.

[0126] Fig.17 . Validation of TREAT, bootstrapping, and jackknife approaches in the independent PEARL Biobank cohort.

[0127] Fig.18 . Diagram of the bioinformatics approach to building an improved AdaBoost model.

[0128] Fig.19 .Relative abundance of genes utilized by the improved AdaBoost model and their predictive power in independent datasets.

[0129] Fig. 20 C-RNA signatures specific for preeclampsia were identified in Nextera Flex generated libraries using standard TREAT analysis and jackknife cutting.

[0130] Fig.21 The relative abundance of genes used by the improved AdaBoost model in the library generated by Nextera Flex and its predictive ability in the RGH14 dataset.

[0131] Figures 22A-22D . Validation of a clinically friendly whole-exome C-RNA analysis method. Fig.22A is a schematic diagram of the sequencing library preparation method; all steps after blood collection can be performed in a centralized processing laboratory. The temporal distribution of transcripts varies throughout pregnancy ( Fig. 22B ). Overlap of genes identified in the C-RNA pregnancy progression study ( Fig. 22C Tissues expressing 91 genes unique to the time course of pregnancy ( Fig.22D ).

[0132] Figures 23A-23C .Sample collection for PE clinical studies. Figure illustrates the iPC study ( Fig.23A ) and PEARL studies ( Fig. 23B ) for each individual in the cohort. The red line indicates the threshold for term birth. The preterm birth rate was significantly increased in the early-onset PE cohort ( Fig.23C ). ***p<0.001, by Fisher's exact test.

[0133] Figures 24A-24G Differential analysis of C-RNAs identifies preeclampsia biomarkers. Fold changes and abundance of altered transcripts in PE ( Fig.24A After cutting each gene detected by standard analysis methods, a one-sided confidence p value interval was calculated ( Fig. 24B ). Transcript abundance fold changes determined by whole exome sequencing and qPCR for (21) genes ( Fig.24C ). *p<0.05, by Student's T test. Tissue distribution of affected genes ( Fig.24D). Hierarchical clustering of iPC samples (average linkage, squared Euclidean distance) ( Fig.24E ). Early-onset PE from the PEARL study ( Fig.24F ) and late-onset PE ( Figure 24G )Clustering of samples.

[0134] Figures 25A-25E AdaBoost classifies preeclampsia samples from all cohorts. Heatmap illustrates the relative abundance of transcripts used by machine learning in each cohort ( Fig.25A ). The height of each block reflects the importance of each gene. The ROC curve of each data set ( Fig.25B ). Distribution of AdaBoost scores (KDE). The orange line indicates the best boundary for distinguishing PE and control samples ( Fig.25C ). The consistency of genes identified by differential analysis with those used in AdaBoost ( Fig.25D ). Tissue distribution of AdaBoost genes ( Fig.25E ).

[0135] Figures 26A-26C .Integrity of C-RNA data when blood is stored in different collection tubes. Comparison of the abundance of C-RNA pregnancy markers previously detected in blood stored overnight in different types of tubes with that processed immediately after collection in EDTA tubes ( Fig.26A ). Scatter plot comparing the FPKM values ​​of C-RNA transcripts prepared from the same individual after different blood storage times ( Fig.26B ). When using EDTA tubes, the Pearson correlation coefficient R is more variable (see Cell-free)( Fig.26C ).

[0136] Fig.27A and 27B Effect of plasma volume on C-RNA data quality. A meta-analysis was performed using data from nine independent studies to determine the appropriate plasma input for this protocol. Noise (biological coefficient of variation, EdgeR) was calculated from the biological replicates in each study ( Fig.27A ). Calculate the library complexity of each sample (combining population, Preseq) ( Fig.27B ). **p<0.01, ***p<0.001 by ANOVA with Tukey HSD correction, with study as blocking variable.

[0137] Figures 28A-28C . Tissue specificity of pregnancy markers. The pie chart shows the relationship between the expression of the entire set of altered genes ( Fig.28A ), for each study-unique transcript ( Fig.28B ) or the intersecting gene sets ( Fig.28C ) Tissue specificity of genes detected in pregnancy.

[0138] Figures 29A-29E . Jackknife cutting excludes genes that are not commonly altered in preeclampsia. Schematic diagram of the jackknife cutting method used to determine the consistency of transcript changes between PE samples ( Fig.29A ). The average abundance and noise of each differentially abundant gene ( Fig.29B The ROC area under the curve value for each affected transcript provides a measure of the abundance distribution of the isolated C-RNA transcripts for the control and PE samples ( Fig.29C ). *p<0.05, by Mann-Whitney U test. Hierarchical clustering of iPC samples using genes excluded after jackknife cutting ( Fig.29D ). Tissue distribution of excluded transcripts ( Fig.29E ). The reduced contribution of the fetus and placenta may indicate that the maternal component of PE is most variable between individuals.

[0139] Figures 30A-30D .AdaBoost model development strategy. The RGH014 dataset is divided into 6 parts ( Fig. 30A The “retained subset” contains 10% of the samples (selected randomly) and 3 samples that could not be clustered correctly when using differentially abundant genes (e.g. Fig.24C ) and were completely excluded from model building. The remaining samples were randomly divided into 5 evenly sized "test subsets". For each test subset, the training data consisted of all non-retained and non-test samples. The gene counts of the training and test data were TMM-normalized in edgeR and then standardized to a mean of 0 and a standard deviation of 1 for each gene. For each training / test sample set, 10 AdaBoost models (with an estimator of 90 and a learning rate of 1.6) were built from the training data ( Fig. 30B ). Feature pruning was performed, removing genes below an increasing importance threshold, and performance was evaluated by the Matthew correlation coefficient when predicting the test data. The model with the best performance (or the fewest genes in case of a tie) was retained. The estimators from all 50 independent models were combined into a single AdaBoost model ( Fig. 30C The resulting set was subjected to feature pruning, this time using the percentage of models using genes to set the threshold, and the performance measured by the average log loss value of the test subset. The ROC curve after applying the final AdaBoost model to the held-out data ( Fig.30D ). All samples were correctly separated except for two of the three samples which were also incorrectly clustered by HCA.

[0140] Figures 31A-31E.The impact of hyperparameter selection and feature pruning on machine learning performance. Heatmap of grid search to identify the best hyperparameters for AdaBoost ( Fig.31A ). The Matthew correlation coefficient is used as the performance metric. The flattened plot of each hyperparameter performance ( Fig.31B ). Arrows indicate the values ​​selected for model building. Fig.31C shows the effect of pruning a single AdaBoost model on performance (e.g. Fig. 30B The solid line is the mean of all 10 models, and the shaded area shows the standard deviation. The number of AdaBoost models used for each gene observed in the pre-pruned set ( Fig.31D ). Model performance when pruning the combined AdaBoost ensemble ( Fig.31E ). Fig.31D and Fig.31E The orange line in shows the threshold used to generate the final AdaBoost model.

[0141] The schematic diagrams are not necessarily drawn to scale. The same reference numerals used in the drawings may refer to the same components. However, it should be understood that the use of a reference numeral to refer to a component in a given drawing is not intended to limit the component to be labeled with the same reference numeral in another drawing. In addition, the use of different reference numerals to refer to components is not intended to indicate that the components with different reference numerals cannot be the same or similar to the components with other reference numerals. DETAILED DESCRIPTION

[0142] Provided herein are circulating RNA signatures found in maternal circulation that are specific for pre-eclampsia, and the use of such signatures in non-invasive methods for the diagnosis of pre-eclampsia and the identification of pregnant women at risk for developing pre-eclampsia.

[0143] Although most DNA and RNA in the body are located inside cells, extracellular nucleic acids can also circulate freely in the blood. Circulating RNA (also referred to herein as "C-RNA") refers to the extracellular segment of RNA found in the bloodstream. C-RNA molecules mainly come from two sources: one is released into the circulation from dying cells in apoptosis, and the other is contained in exosomes shed into the circulation by living cells. Exosomes are small membranous vesicles with a diameter of about 30-150nm released from many cell types into the extracellular space and are present in a variety of body fluids, including serum, urine and breast milk, and carry proteins, mRNA and microRNA. The lipid bilayer structure of exosomes protects the RNA contained therein from being degraded by RNases, thereby providing stability in the blood. See, for example, Huang et al., 2013, BMC Genomics [BMC Genomics]; 14: 319; and Li et al., 2017, Mol Cancer [Molecular Cancer]; 16: 145). There is increasing evidence that exosomes have specialized functions and play a role in coagulation, intercellular signaling, and waste management (van der Pol et al., 2012, Pharmacol Rev; 64(3): 676-705). See also Samos et al., 2006, Ann NY Acad Sci; 1075: 165-173; Zernecke et al., 2009, Sci Signal; 2: ra81; Ma et al., 2012, J Exp Clin Cancer Res; 31: 38; and Sato-Kuwabara et al., 2015, Int J Oncol; 46: 17-27.

[0144] Using the methods described herein, C-RNA molecules found in maternal circulation serve as biomarkers for fetal, placental and maternal health, and provide a window into the progression of pregnancy. This article describes C-RNA signatures in the maternal circulation indicating pregnancy, C-RNA signatures in the maternal circulation temporally associated with the gestational stage of pregnancy, and C-RNA signatures in the maternal circulation indicating the pregnancy complication pre-eclampsia.

[0145] The C-RNA signature in maternal circulation indicative of preeclampsia comprises a plurality of C-RNA molecules encoding at least a portion of a plurality of proteins selected from the group consisting of ARRDC2, JUN, SKIL, ATP13A3, PDE8B, GSTA3, PAPPA2, TIPARP, LEP, RGP1, USP54, CLEC4C, MRPS35, ARHGEF25, CUX2, HEATR9, FSTL3, DDI2, ZMYM6, ST6GALNAC3, GBP2, NES, ETV3, ADAM17, ATOH8, SLC4A3, TRAF3IP1, TTC21A, HEG1, ASTE1, TMEM108, ENC1, SCAMP1, AR , RDC3, SLC26A2, SLIT3, CLIC5, TNFRSF21, PPP1R17, TPST1, GATSL2, SPDYE5, HIPK2, MTRNR2L6, CLCN1, GINS4, CRH, C10orf2, TRUB1, PRG2, ACY3, FAR2, CD63, CKAP4, TPCN1, RNF6, THTPA, FOS, PARN, ORAI3, ELMO3, SMPD3, SERPINF1, TMEM11, PSMD11, EBI3, CLEC4M, CCDC151, CPAMD8, CNFN, LILRA4, ADA, C22orf39, PI4KAP1, and ARFGAP3. The C-RNA signature is an Adaboost universal signature obtained using the TruSeq library preparation method shown in Table 1 below (also referred to herein as "List (a)" or "(a)").

[0146] The C-RNA signature in the maternal circulation indicative of pre-eclampsia includes a plurality of C-RNA molecules encoding at least a portion of a plurality of proteins selected from the group consisting of TIMP4, FLG, HTRA4, AMPH, LCN6, CRH, TEAD4, ARMS2, PAPPA2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, TIMP3, IGFBP5, HSPA12B, CLEC4C, KRT5, PRG2, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, LEP, NES, and VSIG4. The C-RNA signature is a bootstrap signature obtained using the TruSeq library preparation method shown in Table 1 below (also referred to herein as "List (b)" or "(b)").

[0147] The C-RNA signature in maternal circulation indicative of preeclampsia comprises a plurality of C-RNA molecules encoding at least a portion of a protein selected from the group consisting of CYP26B1, IRF6, MYH14, PODXL, PPP1R3C, SH3RF2, TMC7, ZNF366, ADCY1, C6, FAM219A, HAO2, IGIP, IL1R2, NTRK2, SH3PXD2A, SSUH2, SULT2A1, FMO3, FSTL3, GATA5, HTRA1, C8B, H 19. MN1, NFE2L1, PRDM16, AP3B2, EMP1, FLNC, STAG3, CPB2, TENC1, RP1L1, A1CF, NPR1, TEK, ERRFI1, ARHGEF15, CD34, RSP O3, ALPK3, SAMD4A, ZCCHC24, LEAP2, MYL2, NRG3, ZBTB16, SERPINA3, AQP7, SRPX, UACA, ANO1, FKBP5, SCN5A, PTPN21, CACN A1C, ERG, SOX17, WWTR1, AIF1L, CA3, HRG, TAT, AQP7P1, ADRA2C, SYNPO, FN1, GPR116, KRT17, AZGP1, BCL6B, KIF1C, CLIC5 , GPR4, GJA5, OLAH, C14orf37, ZEB1, JAG2, KIF26A, APOLD1, PNMT, MYOM3, PITPNM3, TIMP4, HTRA4, AMPH, LCN6, CRH, TEAD4 , ARMS2, PAPPA2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, TIMP3, IGFBP5, HSPA12B, PRG2, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, LEP, NES, VSIG4, HBG2, CADM2, LAMP5, PTGDR2, NOMO1, NXF3, PLD4, BPIFB3, PACSIN1, CUX2, FLG, CLEC4C, and KRT5. The C-RNA signatures are standard DEX Treat signatures obtained using the TruSeq library preparation method shown in Table 1 below (also referred to herein as "List (c)" or "(c)").

[0148] The C-RNA signature in the maternal circulation indicative of pre-eclampsia comprises a plurality of C-RNA molecules encoding at least a portion of a protein selected from the group consisting of VSIG4, ADAMTS2, NES, FAM107A, LEP, DAAM2, ARHGEF25, TIMP3, PRX, ALOX15B, HSPA12B, IGFBP5, CLEC4C, SLC9A3R2, ADAMTS1, SEMA3G, KRT5, AMPH, PRG2, PAPPA2, TEAD4, CRH, PITPNM3, TIMP4, PNMT, ZEB1, APOLD1, PLD4, CUX2, and HTRA4. The C-RNA signature is a jacknifing signature obtained using the TruSeq library preparation method shown in Table 1 below (also referred to herein as "List (d)" or "(d)").

[0149] The C-RNA signature in the maternal circulation indicative of pre-eclampsia includes a plurality of C-RNA molecules encoding at least a portion of a protein selected from the group consisting of ADAMTS1, ADAMTS2, ALOX15B, AMPH, ARHGEF25, CELF4, DAAM2, FAM107A, HSPA12B, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LEP, LRRC26, NES, OLAH, PACSIN1, PAPPA2, PRX, PTGDR2, SEMA3G, SLC9A3R2, TIMP3, and VSIG4. The C-RNA signature is a standard DEX Treat signature obtained using the Nextera Flex for Enrichment library preparation method shown in Table 1 below (also referred to herein as "List (e)" or "(e)").

[0150] The C-RNA signature in the maternal circulation indicative of pre-eclampsia comprises a plurality of C-RNA molecules encoding at least a portion of a protein selected from the group consisting of ADAMTS1, ADAMTS2, ALOX15B, ARHGEF25, CELF4, DAAM2, FAM107A, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LEP, LRRC26, NES, OLAH, PRX, PTGDR2, SEMA3G, SLC9A3R2, TIMP3, and VSIG4. The C-RNA signature is a jackknife signature obtained using the Nextera Flex for Enrichment library preparation method shown in Table 1 below (also referred to herein as "List (f)" or "(f)").

[0151] The C-RNA signature in the maternal circulation indicating pre-eclampsia includes a plurality of C-RNA molecules encoding at least a portion of a protein selected from CLEC4C, ARHGEF25, ADAMTS2, LEP, ARRDC2, SKIL, PAPPA2, VSIG4, ARRDC4, CRH, and NES. The C-RNA signature is an Adaboost improved TruSeq signature obtained using the TruSeq library preparation method shown in Table 1 below (also referred to herein as "AdaBoost improved version 1", "list (g)" or "(g)").

[0152] In some embodiments, the C-RNA signature in maternal circulation indicative of pre-eclampsia comprises a C-RNA molecule encoding at least a portion of a protein selected from the group consisting of ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, PAPPA2, and VSIG4 (also referred to herein as "AdaBoost improved version 2"), ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, PAPPA2, SKIL, and VSIG4 (also referred to herein as "AdaBoost improved version 3"), ADAMTS2, ARHGEF25, ARRDC4, CLEC4C, LEP, NES, SKIL, and VS IG4 (also referred to herein as “AdaBoost improved version 4”), ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, CRH, LEP, PAPPA2, SKIL and VSIG4 (also referred to herein as “AdaBoost improved version 5”), ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP and SKIL (also referred to herein as “AdaBoost improved version 6”), or ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, LEP, PAPPA2 and SKIL (also referred to herein as “AdaBoost improved version 7”).

[0153] The C-RNA markers in the maternal circulation indicating pre-eclampsia include a plurality of C-RNA molecules encoding at least a portion of a protein selected from the group consisting of LEP, PAPPA2, KCNA5, ADAMTS2, MYOM3, ATP13A3, ARHGEF25, ADA, HTRA4, NES, CRH, ACY3, PLD4, SCT, NOX4, PACSIN1, SERPINF1, SKIL, SEMA3G, TIPARP, LRRC26, PHEX, LILRA4, and PER1. The C-RNA markers are Adaboost improved Nextera Flex markers obtained using the Nextera Flex for Enrichment library preparation method shown in Table 1 below (also referred to herein as "List (h)" or "(h)").

[0154] In some embodiments, the C-RNA signature within the maternal circulation indicative of pre-eclampsia comprises a plurality of C-RNA molecules encoding at least a portion of a protein selected from any one or more of (a), (b), (c), (d), (e), (f), (g) and / or (h) in combination with any one or more of (a), (b), (c), (d), (e), (f), (g) and / or (h).

[0155] The example provided here describes eight kinds of gene lists summarized above, which distinguish pre-eclampsia and control pregnancy.Each is identified by using different analytical methods and / or different data sets.However, there is a high degree of consistency between many of these gene sets.The transcripts that change as in pre-eclampsia C-RNA are identified by a variety of methods, indicating that the transcript has a higher predictive value for the classification of the disease.Therefore, the importance of the transcripts identified by all differential expression analyses and by all AdaBoost models is merged and ranked.The genes with lower rankings are not insignificant or insufficient information, but they may not be so reliable for the classification of pre-eclampsia in the entire cohort and sample preparation.

[0156] First, transcripts identified when all differential expression analyses (standard DEX Treat, bootstrap, and jackknife) were used for both library preparation methods (TruSeq and Nextera Flex for Enrichment) were combined. Table 2 below shows the relative importance of all 125 transcripts identified by the different analysis methods. Transcripts identified in each analysis method and both library preparations were the strongest classification models and were assigned an importance ranking of 1. Transcripts identified by three or more analysis methods and detected with two library preparations were given an importance ranking of 2. Transcripts identified with the most stringent analysis method (jackknife) but only one library preparation were assigned an importance ranking of 3. Transcripts identified in two of the five analysis methods were given an importance ranking of 4. Transcripts identified only in the standard DEX Treat method (the broadest and most inclusive analysis) were given the lowest importance ranking of 5.

[0157] Then, 91 transcripts identified in all AdaBoost models (AdaBoost common version and AdaBoost improved version) and two kinds of library preparations (Table 3 below) are merged.When generating the improved version AdaBoost model for each library preparation, each time when the model is constructed by the same data, the observed subtle changes are observed in the gene set obtained.This is the natural result of the randomness used by AdaBoost to search for large-scale all-exon C-RNA data.In order to obtain a representative gene list, the model construction for improved version AdaBoost has been carried out for a minimum of 9 independent runs, and all genes used by one or more models have been reported.Table 3 (the frequency used by AdaBoost) reports the model percentage including each transcript.AdaBoost assigns its own "importance" value to each transcript, and this value reflects how much influence the abundance of the transcript has on determining whether the sample is from a pre-eclampsia patient.These AdaBoost importance values ​​are averaged (Table 3, average AdaBoost model importance) in each improved version AdaBoost model using a given transcript.

[0158] Transcripts identified in all AdaBoost analyses and library preparations were assigned the highest importance rank of 1. Transcripts identified in the modified AdaBoost model for a single library preparation approach were assigned an importance rank of 2 with AdaBoost usage frequency exceeding 90%. In general, these transcripts also had higher AdaBoost model importances, consistent with increased predictive power. Transcripts identified in the modified AdaBoost model for a single library preparation approach but used by less than 90% of the AdaBoost models were assigned an importance rank of 3. Transcripts identified only in the normal AdaBoost model for a single library preparation were given the lowest importance rank of 4.

[0159] Table 2 lists every gene identified by DEX analysis in all analysis methods and library preparations. Rank 1 = Transcript identified in every analysis method and library preparation method. Rank 2 = Transcript identified in both library preparations and 3 / 5 analysis methods. Rank 3 = Identified in one library preparation method and jackknife (the most stringent analysis). Rank 4 = Identified in 2 / 5 analyses. And, Rank 5 = Identified only in the standard DEX Treat method (our most relaxed analysis method).

[0160] Table 3 lists each gene identified by Adaboost analysis in both library preparations. Rank 1 = identified in both library preparation methods and the improved Adaboost model. Rank 2 = identified in one library preparation method, present in the improved Adaboost model with high model importance and frequency. Rank 3 = identified in one library preparation method, present in the improved Adaboost model with medium model importance and frequency. And, Rank 4 = identified in one library preparation, not present in the improved Adaboost model.

[0161] Table 4 below is a glossary of all the various genes described herein. This information was obtained from the HUGO Gene Nomenclature Committee of the European Bioinformatics Institute.

[0162] Table 1: List of compound genes

[0163]

[0164]

[0165]

[0166]

[0167] Table 2: DEX analysis

[0168]

[0169]

[0170]

[0171]

[0172] Table 3: Adaboost analysis

[0173]

[0174]

[0175]

[0176] Table 4: Gene vocabulary

[0177]

[0178]

[0179]

[0180]

[0181]

[0182]

[0183] The term "plurality" refers to more than one element. For example, the term herein refers to a plurality of C-RNA molecules used as a marker indicating pre-eclampsia.

[0184] A plurality can include any two, any three, any four, any five, any six, any seven, any eight, any nine, any ten, any eleven, any twelve, any thirteen, any fourteen, any fifteen, any sixteen, any seventeen, any eighteen, any nineteen, any twenty, any twenty-one, any twenty-two, any twenty-three, any twenty-four, any twenty-five, any twenty-six, any twenty-seven, any twenty-eight, any twenty-nine, any thirty, any thirty-one, any thirty-two, any thirty-three, any thirty-four , thirty-five, thirty-six, thirty-seven, thirty-eight, thirty-nine, forty, forty-one, forty-two, forty-three, forty-four, forty-five, forty-six, forty-seven, forty-eight, forty-nine, fifty, fifty-one, fifty-two, fifty-three, fifty-four, fifty-five, fifty-six, fifty-seven, fifty-eight, fifty-nine, sixty, sixty-one, sixty-two, sixty-three, sixty-four, sixty-five, Sixty-six, sixty-seven, sixty-eight, sixty-nine, seventy, seventy-one, seventy-two, seventy-three, seventy-four, seventy-five, seventy-six, seventy-seven, seventy-eight, seventy-nine, eighty, eighty-one, eighty-two, eighty-three, eighty-four, eighty-five, eighty-six, eighty-seven, eighty-eight, eighty-nine, ninety, ninety, ninety-one, ninety-two, ninety-three, ninety-four, ninety-five, ninety-six, ninety-two 17, any ninety-eight, any ninety-nine, any one hundred, any one hundred, any one hundred and one, any one hundred and two, any one hundred and three, any one hundred and four, any one hundred and five, any one hundred and six, any one hundred and seven, any one hundred and eight, any one hundred and nine, any one hundred and ten, any one hundred and eleven, any one hundred and twelve, any one hundred and thirteen, any one hundred and fourteen, any one hundred and fifteen, any one hundred and six, any one hundred and seven, any one hundred and eight, any one hundred and nine, any one hundred and ten, any one hundred and eleven, any one hundred and twelve, any one hundred and thirteen, any one hundred and fourteen, any one hundred and fifteen, any one hundred and sixteen, any one hundred and seventeen, any one hundred and eighteen, any one hundred and nineteen, any one hundred and twenty, any one hundred and twenty-one or any one hundred and twenty-two. A plurality of can include at least any one of the numerical value described above. A plurality of can include any one of the numerical value described above. A plurality of can include the scope of any one of the above-described ones. In certain embodiments, the C-RNA mark indicating preeclampsia only includes one of the biomarkers described above.

[0185] Identification and / or quantification of one of these C-RNA markers in a sample obtained from a subject can be used to determine that the subject has pre-eclampsia or is at risk of developing pre-eclampsia.

[0186] The sample can be a biological sample (biological sample or biosample), including but not limited to blood, serum, plasma, sweat, tears, urine, sputum, lymph, saliva, amniotic fluid, tissue biopsy, swab or smear, including, for example but not limited to placental tissue samples. In some preferred embodiments, the biological sample is a cell-free plasma sample. The biological sample can be a maternal sample obtained from a pregnant subject.

[0187] As used herein, the term "subject" refers to human subjects as well as non-human mammalian subjects. Although the examples herein relate to humans and the language is primarily directed to human issues, the concepts of the present disclosure are applicable to any mammal and can be used in veterinary medicine, animal science, research laboratories, and the like.

[0188] The subject can be a pregnant woman, including a pregnant woman at any gestational stage of pregnancy. The gestational stage of pregnancy can be, for example, early, mid, including mid-late, or late, including early late. The gestational stage of pregnancy can be, for example, before 16 weeks of pregnancy, before 20 weeks of pregnancy, or after 20 weeks of pregnancy. The gestational stage of pregnancy can be, for example, 8-18 weeks of pregnancy, 10-14 weeks of pregnancy, 11-14 weeks of pregnancy, 11-13 weeks of pregnancy, or 12-13 weeks of pregnancy.

[0189] The discovery of cell-free fetal nucleic acids in maternal plasma has opened up new possibilities for noninvasive prenatal diagnosis. In the past few years, many approaches have been demonstrated to utilize this circulating fetal nucleic acid for prenatal detection of chromosomal aneuploidy. For example, in Poon et al., 2000, Clin Chem;1832-4; ​​Poon et al., 2001, Ann NY Acad Sci;945:207-10; Ng et al., 2003, Clin Chem;49(5):727-31; Ng et al., 2003, Proc Natl Acad Sci US A.;100(8):4748-53; Tsui et al., 2004, J Med Genet;41(6):461-7; Go et al., 2004, Clin Chem;50(8):1413-4; Smets et al., 2006, Clin Chim Acta [Acta Clinical Chemistry]; 364(1-2):22-32; Tsui et al., 2006, Methods Mol Biol [Methods in Molecular Biology]; 336:123-34; Purwosunu et al., 2007, Clin Chem [Clinical Chemistry]; 53(3):399-404; Chim et al., 2008, Clin Chem [Clinical Chemistry]; 54(3):482-90; Tsui and Lo, 2008, Methods Mol Biol [Methods in Molecular Biology]; 444:275-89; Lo, 2008, Ann NY Acad Sci [Annals of the New York Academy of Sciences]; 1137:140-143; Miura et al., 2010, Prenat Diagn [Prenatal Diagnosis]; 30(9):849-61; Li et al., 2012, Clin Chim Acta [Acta Clinical Chem]; 413(5-6):568-76; Williams et al., 2013, Proc Natl Acad Sci USA [Proceedings of the National Academy of Sciences of the United States of America]; 110(11):4255-60; Tsui et al., 2014, Clin Chem [Clinical Chemistry]; 60(7):954-62; Tsang et al., 2017, Proc Natl Acad Sci USA [Proceedings of the National Academy of Sciences of the United States of America]; 114(37):E7786-E7795 and any of the methods described in U.S. Patent Publication US 2014 / 0243212 can be used for the methods described herein.

[0190] The detection and identification of C-RNA signature biomarkers in the maternal circulation that indicate pre-eclampsia or a risk of developing pre-eclampsia may involve any of a variety of techniques. For example, the biomarkers may be detected in serum by radioimmunoassay, or polymerase chain reaction (PCR) techniques may be used.

[0191] In various embodiments, identification of biomarkers of C-RNA signatures within maternal circulation that indicate pre-eclampsia or risk of developing pre-eclampsia may involve sequencing C-RNA molecules. Any of a variety of sequencing techniques may be used, including but not limited to any of a variety of high-throughput sequencing techniques.

[0192] In some embodiments, the C-RNA population within the maternal biological sample can be enriched for RNA sequences prior to sequencing, wherein the RNA sequences include protein coding sequences. Any of a variety of platforms that can be used for full exon enrichment and sequencing can be used, including but not limited to the Agilent SureSelect Human All Exon platform (Chen et al., 2015a, Cold Spring Harb Protoc [Cold Spring Harb Laboratory Experimental Program]; 2015 (7): 626-33. doi: 10.1101 / pdb.prot083659); Roche NimbleGen SeqCap EZ Exome Library SR platform (Chen et al., 2015b, Cold Spring Harb Protoc [Cold Spring Harb Laboratory Experimental Program]; 2015 (7): 634-41. doi: 10.1101 / pdb.prot084855); or Illumina TruSeq Exome Enrichment platform (Chen et al., 2015c, Cold Spring Harb Protoc [Cold Spring Harbor Laboratory Protocols]; 2015(7):642-8. doi:10.1101 / pdb.prot084863). See also "TruSeq TM Exome Enrichment Guide [TruSeq TM w Exon Enrichment Guide]," Catalog No. FC-930-1012 Part No. 15013230 Rev. B November 2010 and Illumina's "TruSeq TM RNA Sample Preparation Guide,” Catalog No. RS-122-9001 DOC Part No. 15026495 Rev. F March 2014.

[0193] In a particular embodiment, microarray technology can be used to detect and identify biomarkers of C-RNA logos in the maternal circulation indicating pre-eclampsia or the risk of developing pre-eclampsia. In this method, the target polynucleotide sequence is plated or arranged on a microchip substrate. The arranged sequence is then hybridized with a maternal biological sample or its purification and / or enrichment portion. Microarrays can include a variety of solid supports, including but not limited to beads, glass microscope slides, glass wafers, gold, silicon, microchips and other plastics, metals, ceramics or biological surfaces. Microarray analysis can be performed according to the manufacturer's protocol, such as by using the technology of Illumina, by commercially available equipment.

[0194] In order to obtain, transport, store and / or process blood samples for the preparation of circulating RNA, multiple steps can be taken to stabilize the sample and / or prevent disruption of cell membranes, thereby causing the release of cellular RNA into the sample. For example, in some embodiments, before processing into plasma, blood samples can be stored in tubes with cell and DNA stabilization properties, such as Streck Cell-Free DNA The blood sample is collected, transported and / or stored in a blood collection tube. In some embodiments, the blood sample is not exposed to EDTA. See, e.g., Qin et al., 2013, BMC Research Notes [BMC Research Notes]; 6:380 and Medina Diaz et al., 2016, PLoS ONE [Public Library of Science One]; 11(11): e0166354.

[0195] In some embodiments, the blood sample is processed to plasma within about 24 to about 72 hours of blood draw, and in some embodiments, within about 24 hours of blood draw.

[0196] In some embodiments, blood samples are maintained, stored, and / or shipped at room temperature prior to processing into plasma.

[0197] In some embodiments, blood samples are maintained, stored, and / or transported without exposure to cooling (eg, on ice) or freezing prior to processing into plasma.

[0198] The present disclosure includes a kit for diagnosing pre-eclampsia and identifying pregnant women at risk of developing pre-eclampsia. A kit is any article (e.g., packaging or container) comprising at least one reagent (e.g., a probe) for specific detection of C-RNA markers in maternal circulation as described herein indicating pre-eclampsia or having a risk of developing pre-eclampsia. The kit can be promoted, distributed or sold as a unit for performing the method of the present disclosure.

[0199] The circulating RNA mark found in the maternal circulation that has specificity for pre-eclampsia can be combined with appropriate monitoring and medical management in non-invasive methods to diagnose pre-eclampsia and identify the purposes in the pregnant woman with risk of developing pre-eclampsia. For example, further testing may be required. Such tests may include, for example, blood tests to measure liver function, kidney function and / or platelets and various coagulation proteins, urinalysis to measure protein or creatinine levels, fetal ultrasound to monitor fetal growth, weight and amniotic fluid, no stress test to measure fetal heart rate by fetal movement, and / or use ultrasound to carry out biophysical analysis to measure fetal breathing, muscle tension and movement and the volume of amniotic fluid that may be needed. Therapeutic interventions may include, for example, increasing the frequency of antenatal examinations, antihypertensive drugs to reduce blood pressure, corticosteroids, anticonvulsants, bed rest, hospitalization and / or early delivery. See, e.g., Townsend et al., 2016 “Current best practice in the management of hypertensive disorders in pregnancy,” Integr Blood Press Control; 9:79-94.

[0200] Therapeutic interventions may include the use of low-dose aspirin to pregnant women identified as having a risk of developing preeclampsia. A recent multicenter, double-blind, placebo-controlled trial demonstrated that, compared with placebo, the use of low-dose aspirin to treat high-risk women with premature preeclampsia resulted in a lower incidence of the diagnosis (Rolnik et al., 2017, "Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia [preterm preeclampsia high risk of pregnancy aspirin relative to placebo], "N Engl J Med [New England Journal of Medicine]; 377 (7): 613-622). The dosage of low-dose aspirin includes but is not limited to about 50 to about 150 mg per day, about 60 to about 80 mg per day, about 100 or more mg per day, or about 150 mg per day. Application can be, for example, started at or before 16 weeks of pregnancy or 11 to 14 weeks of pregnancy. Application can continue to 36 weeks of pregnancy.

[0201] The present invention is illustrated by the following examples. It should be understood that the specific examples, materials, amounts and procedures should be interpreted broadly in accordance with the scope and spirit of the present invention as set forth herein.

[0202] Examples

[0203] Example 1

[0204] Unique C-RNA signature for pregnancy

[0205] The presence of circulating nucleic acids in maternal plasma provides a window into the progression and health of the fetus and placenta ( Figure 1 Circulating RNA (C-RNA) has been detected in the maternal circulation and originates from two major sources. A large portion of C-RNA originates from apoptotic cells, which release vesicles containing C-RNA into the bloodstream. C-RNA also enters the maternal circulation through the shedding of active signaling vesicles (e.g., exosomes and microvesicles) from various cell types. Figure 2 As shown, C-RNA is therefore composed of byproducts of cell death as well as active signaling products. Characteristics of C-RNA include being generated by common processes, released from cells throughout the body, and being stable and contained in vesicles. It represents a circulating transcriptome that reflects tissue-specific changes in gene expression, signaling, and cell death.

[0206] C-RNA may be an excellent biomarker for at least the following reasons:

[0207] 1) All C-RNAs are contained in membrane-bound vesicles, which protect C-RNAs from degradation, making them very stable in the blood.

[0208] 2) C-RNA is derived from all cell types. For example, it has been shown that C-RNA contains transcripts from the placenta and the developing fetus. The multiple sources of C-RNA make it a rich repository for obtaining information about fetal and overall maternal health.

[0209] C-RNA libraries were prepared from plasma samples using standard Illumina library preparation and whole exon enrichment techniques. Figure 3 Specifically, Illumina TruSeq TM Library preparation and RNA access enrichment. Using this approach, libraries were generated with 90% reads aligned to human coding regions ( Figure 3 and Figure 7 ). Samples were downsampled to 50M reads and ≥40M mapped reads were used for downstream analysis. Figure 3 Samples processed as shown in the C-RNA workflow. Dual index library. 50X 50 sequencing on HiSeq2000.

[0210] like Figure 4As shown, plasma samples from late pregnant women were compared with results from plasma samples from non-pregnant women, resulting in a clear signature unique to pregnancy. The top 20 differentially abundant genes for this signature were CSHL1, CSH2, KISS1, CGA, PLAC4, PSG1, GH2, PSG3, PSG4, PSG7, PSG11, CSH1, PSG2, HSD3B1, GRHL2, LGALS14, FCGR1C, PSG5, LGALS13, and GCM1. Most of the genes identified in the pregnancy signature are placenta expressed and also correlate with published data. These results also confirm that placental RNA can enter the maternal circulation.

[0211] Example 2

[0212] C-RNA signature across gestational ages

[0213] This example characterizes the C-RNA signature across different gestational ages throughout pregnancy. It is expected that the changes in the C-RNA signature at different time points throughout pregnancy will be more subtle than the differences between the C-RNA signatures of pregnant and non-pregnant samples noted in Example 1. Figure 5 As shown, as pregnancy progresses, the C-RNA profiles of the marker genes are observed to change significantly over time, with a clear group of genes upregulated in the early stage and a clear group of genes increased in the late stage.

[0214] These genes include CGB8, CGB5, ZSCAN23, HSPA1A, PMAIP1, C8orf4, ITM2B, IFIT2, CD74, HSPA6, TFAP2A, TRPV6, EXPH5, ​​CAPN6, ALDH3B2, RAB3B, MUC15, GSTA3, GRHL2, and CSHL1. Figure 5 The listed.

[0215] These genes may also include CSHL1, CSH2, KISS1, CGA, PLAC4, PSG1, GH2, PSG3, PSG4, PSG7, PSG11, CSH1, PSG2, HSD3B1, GRHL2, LGALS14, FCGR1C, PSG5, LGALS13 and GCM1.

[0216] These changes throughout pregnancy correlate with published data from Steve Quake and Dennis Lo. See, e.g., Maron et al., 2007, “Gene expression analysis in pregnant women and their infants identifies unique fetal biomarkers that circulate in maternal blood,” J Clin Invest; 117(10):3007-3019; Koh et al., 2014, “Noninvasive in vivo monitoring of tissue-specific global gene expression in humans,” Proc Natl Acad Sci USA; 111(20):7361-6; and Ngo et al., 2018, “Noninvasive blood tests for fetal development predict gestational age and preterm delivery,” Science; 360(6393):1133-1136. The researchers found a C-RNA signature that correlated with placental gene expression patterns. This approach could therefore detect subtle changes during pregnancy and provide a non-invasive means to monitor placental health.

[0217] Example 3

[0218] C-RNA signature of preeclampsia

[0219] In the case of this example, a unique C-RNA signature for pre-eclampsia was identified. The C-RNA signature was determined in samples collected from pregnant women diagnosed with pre-eclampsia in two studies (the RGH14 study (registered as NCT0208494 in clinical trials.gov) and the Pearl study (also referred to herein as the Pearl Biobank; registered as NCT02379832 in clinical trials.gov)) and analyzed ( Figure 6). Two tubes of blood were collected at the time of diagnosis of pre-eclampsia. Eighty gestational age-matched control samples were collected to minimize transcriptional variability unrelated to pre-eclampsia disease status and to control for gestational age differences in C-RNA signatures. Samples from the RGH14 study were used to identify a set of biologically relevant genes, and the predictive value of these biomarkers was validated in an independent cohort of samples from the Pearl Biobank.

[0220] In the RGH14 data analysis, unique C-RNA signatures for pre-eclampsia (PE) were identified using four different methods: TREAT method, bootstrap method, jackknife method, and Adaboost method. Example 3 focuses on the first three analysis methods, and Example 4 focuses on the Adaboost method.

[0221] The t-test relative to a threshold (TREAT) statistical method using the EDGR program allows researchers to formally test (with an associated p-value) whether differential expression in a microarray experiment is greater than a given (biologically meaningful) threshold. For a more detailed description of the TREAT statistical method, see McCarthy and Smyth, 2009, "Testing significance relative to a fold-change threshold is a TREAT," Bioinformatics; 25(6): 765-71, and for a more detailed description of the EDGR program, see Robinson et al., 2010, "edgeR: a Bioconductor package for differential expression analysis of digital gene expression data," Bioinformatics; 26: 139-140. For a more detailed description of the Adaboost method, see Freund and Schapire, 1997, "A Decision-Theoretic Generalization of On-Line Learning and an Application to Boosting," Journal of Computer and Systems Sciences; 55(1): 119-139 and Pedregosa et al., 2011, "Scikit-learn: Machine Learning in Python," JMLR; 12: 2825-2830. The Adaboost method will be discussed in Example 4.

[0222] In the first approach, standard statistical tests (TREAT method) were used to identify genes that were statistically different in the RGH14 preeclampsia cohort of 40 patients compared to a subset of matched controls (40 patients). 122 genes were identified as statistically different in the preeclampsia cohort (40 patients) compared to a subset of matched controls (40 patients). Figure 8, right). These genes include CYP26B1, IRF6, MYH14, PODXL, PPP1R3C, SH3RF2, TMC7, ZNF366, ADCY1, C6, FAM219A, HAO2, IGIP, IL1R2, NTRK2, SH3PXD2A, SSUH2, SULT2A1, FMO3, FSTL3, GATA5, HTRA1, C8B, H19, MN1, NFE2L1, PRDM16, AP3B2, EMP1, FLNC , STAG3, CPB2, TENC1, RP1L1, A1CF, NPR1, TEK, ERRFI1, ARHGEF15, CD34, RSPO3, ALPK3, SAMD4A, ZCCHC24, LEAP2, MYL2, NRG3, ZBTB16, SERPINA3, AQP7, SRPX, UACA, ANO1, FKBP5, SCN5A, PTPN21, CACNA1C, ERG, SOX17, WWTR1, AIF1 L, CA3, HRG, TAT, AQP7P1, ADRA2C, SYNPO, FN1, GPR116, KRT17, AZGP1, BCL6B, KIF1C, CLIC5, GPR4, GJA5, OLAH, C1 4orf37, ZEB1, JAG2, KIF26A, APOLD1, PNMT, MYOM3, PITPNM3, TIMP4, HTRA4, AMPH, LCN6, CRH, TEAD4, ARMS2, PAPPA 2. SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, TIMP3, IGFBP5, HSPA12B, PRG2, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM10 7A, LEP, NES, VSIG4, HBG2, CADM2, LAMP5, PTGDR2, NOMO1, NXF3, PLD4, BPIFB3, PACSIN1, CUX2, FLG, CLEC4C and KRT5.

[0223] The TREAT method did not identify a set of genes that could 100% accurately classify preeclampsia patients into separate groups ( Fig.15 ). However, focusing on these identified genes did improve classification compared to using the entire dataset of all measured genes ( Figure 8 , left). This highlights the value of focusing on a subset of genes for prediction. However, in the case of the TREAT approach, a large variability was observed in the genes identified depending on the controls chosen. To account for this biological variability and further improve the predictive value of our gene list, a second bootstrapping approach was developed.

[0224] In the RGH14 study, more control samples (80) were available than pre-eclampsia patient samples (40). Therefore, the RGH14 cohort of 40 pre-eclampsia patient samples was compared with a random selection of 40 control samples (still matched for gestational age), and a list of genes that were statistically different in the pre-eclampsia cohort was identified. Fig. 9 This was then repeated 1,000 times to identify how often a set of genes were identified. In 1,000 iterations, a significant subset of genes appeared less than 10 times (less than 1% of 1,000 iterations). These low-frequency genes are likely due to biological noise and may not reflect genes that are generally specific to preeclampsia. Therefore, a gene was considered statistically significant in the preeclampsia cohort only if it was identified in 50% of the 1,000 iterations performed, further reducing the selected gene list ( Fig. 9 , right). Fig.10 As shown, differential transcript abundance and additional bootstrap selection distinguished pre-eclampsia samples from healthy controls. Using this additional requirement helped account for biological variability and further improved the ability to correctly classify pre-eclampsia samples.

[0225] Using this bootstrap approach, 27 genes were identified that were statistically associated with preeclampsia. These genes include TIMP4, FLG, HTRA4, AMPH, LCN6, CRH, TEAD4, ARMS2, PAPPA2, SEMA3G, ADAMTS1, ALOX15B, SLC9A3R2, TIMP3, IGFBP5, HSPA12B, CLEC4C, KRT5, PRG2, PRX, ARHGEF25, ADAMTS2, DAAM2, FAM107A, LEP, NES, and VSIG4. The genes identified using this bootstrap approach showed excellent consistency with published data. Approximately 75% of these genes are expressed by the placenta. Fig.11 As shown, there is overlap with known markers of pre-eclampsia, including PAPPA and CRH. Furthermore, a large number of these genes are involved in embryonic development, extracellular matrix remodeling, immune regulation, and cardiovascular function, all pathways known to be dysregulated in pre-eclampsia.

[0226] A third jackknife approach was also developed to capture the subset of genes with the highest predictive value. This approach is similar to the bootstrap approach. Patients with preeclampsia and controls were randomly subsampled and differentially abundant genes were identified 1,000 times. Rather than using the frequency with which a gene was identified as statistically different, the jackknife approach calculated a confidence interval (95%, one-sided) for the p-value for each transcript. Genes with confidence intervals exceeding 0.05 were excluded. ( Fig.16 , left picture).

[0227] Using the jackknife approach, 30 genes were identified to predict preeclampsia: VSIG4, ADAMTS2, NES, FAM107A, LEP, DAAM2, ARHGEF25, TIMP3, PRX, ALOX15B, HSPA12B, IGFBP5, CLEC4C, SLC9A3R2, ADAMTS1, SEMA3G, KRT5, AMPH, PRG2, PAPPA2, TEAD4, CRH, PITPNM3, TIMP4, PNMT, ZEB1, APOLD1, PLD4, CUX2, and HTRA4.

[0228] like Fig.16 As shown in the figure on the right, this method performs well in classifying preeclampsia patients in the RGH14 dataset (compare Fig.15 (TREAT), Fig.10 (bootstrapped) and Fig.16 Each identified gene list was also used to classify pre-eclampsia samples in an independent Pearl Biobank dataset. Fig.17 As shown, each gene list was able to classify pre-eclampsia samples.

[0229] All genes identified by bootstrapping and jackknife are represented by 122 TREAT method genes (Table 2, DEX analysis, TruSeq library preparation method). The gene lists of bootstrapping and jackknife were highly consistent, with more than 70% of the common genes. Nearly 90% of the transcripts identified by any method showed increased transcript abundance in patients with preeclampsia, which is consistent with the increase in signal transduction and / or cell death in this disease.

[0230] Example 4

[0231] Identification of C-RNA markers using Adaboost

[0232] In this example, an alternative approach (a publicly available machine learning algorithm called adaboost) was used to identify specific C-RNA signatures associated with pre-eclampsia. Fig.12 As shown in Figure 2, this approach identified a set of genes with the greatest predictive power to classify samples as preeclampsia (PE) or normal. Using this gene list, the clearest separation of the preeclampsia cohort from healthy controls was observed. However, this approach is also prone to overtraining the samples used to build the model. Therefore, the predictive model was validated using a completely independent dataset from the PEARL study ( Fig.13 Using this Adaboost gene list, 85% of preeclampsia samples could be accurately classified with 85% specificity ( Fig.14). Overall, the Adaboost machine learning method built the most accurate prediction model for preeclampsia.

[0233] Using the Adaboost method, 75 genes statistically associated with preeclampsia were identified (Table 3, AdaBoost analysis, TruSeq library preparation method). These genes include ARRDC2, JUN, SKIL, ATP13A3, PDE8B, GSTA3, PAPPA2, TIPARP, LEP, RGP1, USP54, CLEC4C, MRPS35, ARHGEF25, CUX2, HEATR9, FSTL3, DDI2, ZMYM6, ST6GALNAC3, GBP2, NES, ETV3, ADAM17, ATOH8, SLC4A3, TRAF3IP1, TTC21A, HEG1, ASTE1, TMEM108, ENC1, SCAMP1, ARRDC3, SLC26A2, SLIT3, CLIC5, TNFRSF21, PPP1R17, TPST1, GATSL2, SPDYE5, HIPK2, MTRNR2L6, CLCN1, GINS4, CRH, C10orf2, TRUB1, PRG2, ACY3, FAR2, CD63, CKAP4, TPCN1, RNF6, TH TPA, FOS, PARN, ORAI3, ELMO3, SMPD3, SERPINF1, TMEM11, PSMD11, EBI3, CLEC4M, CCDC151, CPAMD8, CNFN, LILRA4, ADA, C22orf39, PI4KAP1 and ARFGAP3.

[0234] A modified AdaBoost model was also developed to reliably classify PE samples. To create a general machine learning model that can accurately predict new samples, we used a rigorous approach to avoid overfitting a single dataset and validate the final classification model with samples that were not used for model building. Fig.18 As shown, the RGH14 dataset is divided into 6 parts by random selection: a holdout subset with 12% of the samples excluded from model building, and 5 test subsets of uniform size. For each iteration, the subset is designated as training data or test samples. This process starts with building an AdaBoost model and is repeated a minimum of 10 times for this data subset. After building 50 high-performance models for the 5 test training subsets, the estimators of all models are merged into a single AdaBoost model.

[0235] Using a modified version of the AdaBoost model, 11 genes statistically associated with preeclampsia were identified. These genes included CLEC4C, ARHGEF25, ADAMTS2, LEP, ARRDC2, SKIL, PAPPA2, VSIG4, ARRDC4, CRH, and NES. The performance of this prediction model was validated using a holdout dataset from RGH14 and in a completely independent Pearl Biobank cohort ( Fig.19 ).

[0236] AdaBoost model creation description. The AdaBoost classification method was improved to obtain more specific gene sets (AdaBoost improvements 1-7) by the following method, as well as Fig.18 The RGH14 dataset was randomly divided into 6 parts: a holdout subset with 12% of the samples excluded from model building, and 5 test subsets of uniform size.

[0237] For each test subset, training data is designated as all samples in the retained sample or test sample. The gene counts of the test and training samples are normalized by TMM in edgeR, and then standardized so that the mean of the training data for each gene is 0 and the standard deviation is 1. Then the AdaBoost model with 90 estimators and 1.6 learning rates is fitted to the training data. Feature pruning is then performed by determining the feature importance of each gene in the model and eliminating the influence of the estimator using the gene test with importance lower than the threshold. The threshold value for obtaining the best performance (as measured by the Matthew correlation coefficient of the test data classification) with the least gene is selected, and the model is retained. This process starts with building the AdaBoost model, and this data subset is repeated at least 10 times.

[0238] After all 50+ models were built for the 5 test training subsets, the estimators from all models were merged into a single AdaBoost model. Feature pruning was performed again, this time using the percentage of models that included genes at the threshold, and the performance was evaluated using the average negative log loss value to classify each test subset. The model that achieved the maximum negative log loss value with the fewest genes was selected as the final AdaBoost model.

[0239] AdaBoost gene list. After repeating this process, minor variations were observed in the genes selected by the final model due to the randomness inherent in the AdaBoost algorithm implementation, however, high performance was maintained in predicting the test data, holdout data, and independent (Pearl) datasets.

[0240] A total of 11 genes were observed in at least one of the 14 AdaBoost-modified models generated: ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, CRH, LEP, NES, PAPPA2, SKIL, VSIG4 (AdaBoost-modified 1), although no model was generated that included all of them simultaneously.

[0241] The two gene sets observed provided the highest performance for classifying independent data. These were AdaBoost Improvement 2: ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, PAPPA2, VSIG4 and AdaBoost Improvement 3: ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, PAPPA2, SKIL, VSIG4.

[0242] Four additional gene sets performed almost as well as AdaBoost improvements 2-3. These were AdaBoost improvement 4: ADAMTS2, ARHGEF25, ARRDC4, CLEC4C, LEP, NES, SKIL, VSIG4; AdaBoost improvement 5: ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, CRH, LEP, PAPPA2, SKIL, VSIG4; AdaBoost improvement 6: ADAMTS2, ARHGEF25, ARRDC2, CLEC4C, LEP, SKIL; and AdaBoost improvement 7: ADAMTS2, ARHGEF25, ARRDC2, ARRDC4, CLEC4C, LEP, PAPPA2, SKIL.

[0243] Example 5

[0244] Identification of C-RNA markers using transposome-based library preparation

[0245] RGH14 samples were also processed by Illumina Nextera Flex for Enrichment protocol, enriched for whole exons, and sequenced to >40 million reads. This method is more sensitive and reliable for low input amounts, so additional genes that predict preeclampsia may be identified. This dataset was run through three analysis methods: standard differential expression analysis (TREAT), jackknife, and a modified Adaboost model. See Examples 3 and 4 for detailed descriptions of these analysis methods.

[0246] Changing the method used to generate the library changed the genes detected in all three analytical methods. For the TREAT method, 26 genes with differential abundance in pre-eclampsia were identified, and most of them showed elevated abundance in pre-eclampsia (see Table 2, DEX analysis, Nextera Flex for Enrichment library preparation method). These genes include ADAMTS1, ADAMTS2, ALOX15B, AMPH, ARHGEF25, CELF4, DAAM2, FAM107A, HSPA12B, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LEP, LRRC26, NES, OLAH, PACSIN1, PAPPA2, PRX, PTGDR2, SEMA3G, SLC9A3R2, TIMP3, VSIG4. Fig. 20 Classification of the RGH14 sample with this gene list is shown.

[0247] Jackknife analysis was applied to reduce the TREAT list to 22 genes identified as differentially abundant in preeclampsia. These genes included ADAMTS1, ADAMTS2, ALOX15B, ARHGEF25, CELF4, DAAM2, FAM107A, HTRA4, IGFBP5, KCNA5, KRT5, LCN6, LEP, LRRC26, NES, OLAH, PRX, PTGDR2, SEMA3G, SLC9A3R2, TIMP3, and VSIG4. The improved performance of this list was as follows Fig. 20 shown.

[0248] As described in Example 4, a modified version of the AdaBoost model approach was applied to this data. Using this approach, 24 genes statistically associated with preeclampsia were identified (Table 3, AdaBoost analysis, Nextera Flex for Enrichment library preparation method). These genes include LEP, PAPPA2, KCNA5, ADAMTS2, MYOM3, ATP13A3, ARHGEF25, ADA, HTRA4, NES, CRH, ACY3, PLD4, SCT, NOX4, PACSIN1, SERPINF1, SKIL, SEMAG3, TIPARP, LRRC26, PHEX, LILRA4, and PER1. The performance of this predictive model is shown in Table 3. Fig.21 shown.

[0249] Example 6

[0250] Circulating transcriptome measurements from maternal blood detect markers of early-onset preeclampsia

[0251] Molecular tools for non-invasive monitoring of pregnancy health from pregnancy to birth can accurately detect pregnancies at risk of adverse outcomes. Circulating RNA (C-RNA) is released into the blood by all tissues, allowing for convenient, comprehensive measurements of placental, fetal, and maternal health (Koh et al., 2014, Proceedings of the National Academy of Sciences; 111: 7361-7366; and Tsui et al., 2014, Clinical Chemistry; 60: 954-962). Preeclampsia (PE), a common and potentially fatal pregnancy complication, originates in the placenta, but acquires a large amount of maternal components as the disease progresses (Staff et al., 2013, Hypertension; 61: 932-942; and Chaiworapongsa et al., 2014, Nature Reviews Nephrology; 10, 466-480). However, the claimed biomarkers have shown limited clinical utility (Poon and Nicolaides, 2014, Obstetrics and Gynecology International; 2014: 1-11; Zeisler et al., 2016, N Engl J Med; 374: 13-22; and Duhig et al., 2018, F1000 Research; 7: 242). Assuming that characterization of the circulating transcriptome could identify better biomarkers, C-RNA was analyzed in 113 pregnant women, 40 of whom were at diagnosis of early-onset PE. Using a novel workflow, differences in the abundance of 30 transcripts were identified that were consistent with the biology of PE and represented placental, fetal, and maternal contributions. In addition, a machine learning model was developed that demonstrated that only seven C-RNA transcripts were needed to classify PE into two independent cohorts (with an accuracy of 92%-98%). The overall measurement results of C-RNA disclosed in this example highlight its practicality in monitoring maternal and fetal health and provide broad prospects for the diagnosis and prediction of high-risk pregnancies.

[0252] Several studies have begun to investigate and identify potential biomarkers in C-RNA for a range of pregnancy complications (Pan et al., 2017, Clinical Chemistry; 63: 1695-1704; Whitehead et al., 2016, Prenatal Diagnosis; 36: 997-1008; Tsang et al., 2017, Proc Natl Acad Sci USA; 114: E7786-E7795; and Ngo et al., 2018, Science; 360: 1133-1136). However, these studies have involved few patients and have been limited to monitoring a small number of genes - almost exclusively placental and fetal derived transcripts. Measurements of the entire circulating transcriptome are difficult to perform because they require specific upfront sample collection and processing to minimize variability and contamination from cell lysis (Chiu et al., 2001, Clinical Chemistry; 47:1607-1613; and Page et al., 2013, PLoS ONE; 8:e77963). This complex workflow makes large clinical sample collection difficult to achieve because the manpower required to immediately process blood samples is not feasible for many clinics (Marton and Weiner, 2013, BioMed Research International; 2013:891391). Therefore, in this example case, a method was established that allows blood to be shipped overnight to a processing laboratory where each step of sample preparation is performed in a controlled environment, providing a scalable platform for clinical trial-level evaluation ( Fig.22A ).

[0253] Key to this approach is the ability to ship blood overnight to a processing laboratory. In several tubes, C-RNA pregnancy signals were assessed after overnight shipping at room temperature ( Figures 26A-26C ). Blood stored in EDTA tubes, the gold standard used in previous C-RNA studies, showed a decrease in the abundance of pregnancy-associated transcripts and an overall instability in the transcriptome profile (Qin et al., 2013, BMC Research Notes; 6:380). In contrast, the main tube type used for non-invasive prenatal testing (NIPT), cell-free DNA BCT (Streck), retains signal from placental transcripts and improves technical reproducibility ( Fig.26B)(Medina Diaz et al., 2016, PLoS ONE;11:e0166354).

[0254] Shipping blood allowed us to easily obtain an average of 5 mL of plasma per patient from a single tube of blood. We evaluated the differences in C-RNA data quality when using different plasma volumes and determined that using <2 mL of plasma significantly increased noise and reduced library complexity ( Fig.27A and 27B ). Therefore, 4 mL of plasma was used for the study in this example to maximize confidence in the data quality.

[0255] This novel workflow was validated by outlining prior work that monitored C-RNA dynamics of >10,000 transcripts per healthy pregnancy from early to late pregnancy. Using 152 samples collected serially from 45 healthy pregnancies (Preeclampsia and Growth Restriction Longitudinal Study Control Cohort-PEARL; NCT02379832; Table 5), 156 significantly altered transcripts were identified, most of which increased in abundance as pregnancy progressed ( Fig. 22B ). 42% of the altered genes identified in previous C-RNA studies ( Fig. 22C )(Koh et al., 2014, Proceedings of the National Academy of Sciences; 111:7361-7366; and Tsui et al., 2014, Clinical Chemistry; 60:954-962). Of the 91 transcripts identified in this study alone, 64% were expressed by placental and / or fetal tissues ( Fig.22D and 28A -28C). The remaining genes are presumably a reflection of the maternal response to pregnancy.

[0256] Study Design

[0257] For the next phase of investigation, the workflow was applied to clinical samples to measure changes in C-RNA in PE (iPC, Illumina preeclampsia cohort). PE is a heterogeneous disorder and is associated with different severity and patient outcomes based on whether it occurs before (early-onset) or after (late-onset) 34 weeks of gestation (Staff et al., 2013, Hypertension [high blood pressure]; 61: 932-942; Chaiworapongsa et al., 2014, Nature Reviews Nephrology [natural review: kidney disease]; 10, 466-4803; and Dadelszen et al., 2003, Hypertension in Pregnancy [high blood pressure during pregnancy]; 22: 143-148). This study focused on more severe, early-onset PE and defined strict diagnostic criteria with clear inclusion and exclusion requirements—most critically excluding anyone with a history of chronic hypertension—in order to obtain a clean cohort (Table 6) (Nakanishi et al., 2017, Pregnancy Hypertension; 7:39-43; and Hiltunen et al., 2017, PLoS ONE; 12:e0187729). Maternal characteristics, pregnancy outcomes, and medications used were recorded throughout the study (Table 7). 113 samples were collected at 8 sites (Table 8), 40 samples were at PE diagnosis, and 73 controls were matched for gestational age within 1 week ( Fig.23A All but one of the women with PE delivered preterm, compared with 9.5% of controls, confirming these diagnostic criteria to identify individuals severely affected by the disease ( Fig.23C ).

[0258] All samples were randomly distributed across multiple treatment batches and then sequenced to ≥40M reads. Standard differential expression analysis of the entire cohort identified 42 altered transcripts, 37 of which were elevated in PE ( Fig.24A , blue and orange). However, it is noteworthy that high variability was observed in the genes in which changes were detected when different subsets of controls were chosen for analysis.

[0259] To resolve this discrepancy, a jackknife approach was used, which identifies the most consistently altered genes ( Fig.24A and 24B , orange). 1,000 iterations of differential analysis were performed with randomly selected subsets of samples, which allowed the construction of confidence intervals for the p-values ​​associated with each putatively altered transcript ( Fig.29A ). Twelve genes with confidence intervals exceeding 0.05 were excluded ( Fig. 24BThese genes would not be excluded simply by setting a threshold for baseline abundance or biological divergence ( Fig.29B ), however, it was observed that these transcripts had a lower predictive value ( Fig.29C ). Hierarchical clustering indicated that these genes were not universally altered in the PE cohort and therefore lacked sensitivity (73%) for accurate classification of this condition ( Fig.29D ).

[0260] The analysis then focused on a refined set of 30 genes, 60% of which had been previously associated with PE (Namli et al., 2018, Hypertension in Pregnancy; 37:9-17; Than et al., 2018, Frontiers in Immunology; 9:1661; Kramer et al., 2016, Placenta; 37:19-25; Winn et al., 2008, Endocrinology; 150:452-462; and Liu et al., 2018, Molecular Medicine Reports; 18:2937-2944). qPCR analysis confirmed that 19 of the 20 genes were significantly altered in PE ( Fig.24C , Table 9). Surprisingly, 40% of these genes encode extracellular or secreted protein products. In addition, almost all genes are involved in PE-related processes, including extracellular matrix (ECM) remodeling, pregnancy duration, placental / fetal development, angiogenesis, and hypoxic response (Table 10). 67% of these transcripts are expressed by the placenta and / or fetus ( Fig.24D Of the remaining maternally expressed transcripts, cardiovascular and immune functions were well represented (Table 10). Hierarchical clustering of these genes effectively separated PE and control samples with a sensitivity of 98% and a specificity of 97% ( Fig.24E Interestingly, the clinical data for these two misidentified controls indicated possible confounding health issues, as indicated by their use of hypertension medications (Table 7).

[0261] Using genes identified in iPC, we evaluated the ability to cluster a cohort of samples obtained from an independent biobank—the Preeclampsia and Growth Restriction Longitudinal Study (PEARL; NCT02379832; Fig. 23B and 23C , Table 11). The cohort consisted of early-onset (diagnosed at <34 weeks); and late-onset PE as well as gestational age-matched controls. Early-onset PE samples were clustered separately from matched controls with a sensitivity of 83% and a specificity of 92%, further confirming the relevance of these transcripts ( Fig.24FIn contrast, no clustering was observed for late-onset PE and matched control samples ( Figure 24G ).

[0262] The iPC data were then used to build an AdaBoost model to reliably classify PE samples. To create a general machine learning model that could accurately predict new samples, a rigorous approach was used that avoided overfitting to a single dataset and validated the final classification model with samples that were not used for model building ( Figures 30A-30D and Figures 31A-31E Surprisingly, the final model utilized only 7 genes, 3 of which had not been previously reported ( Fig.25A ). For the entire iPC cohort, this model classified samples with very high accuracy (AUC = 0.99, sensitivity = 98%, specificity = 99%; Fig.25B and 25C , blue). Early-onset PE PEARL samples were also accurately classified (AUC = 0.88, sensitivity = 100%, specificity = 83%; Fig.25B and 25C , pink). Unexpectedly, late-onset PE PEARL samples were also classified with reasonable accuracy (AUC = 0.74, sensitivity = 75%, specificity = 67%; Fig.25B and 25C ,green).

[0263] This gene set was highly consistent with transcripts identified by differential abundance analysis ( Fig.25D ; Table 10). The classification model relies on placental and maternally expressed transcripts ( Fig.25E ). All genes used in the model form extracellular or membrane-bound protein products. Despite the small number of genes selected by AdaBoost, a variety of PE-related functions were observed, particularly cardiovascular function and angiogenesis, immune regulation, fetal development, and ECM remodeling.

[0264] method

[0265] Prospective clinical sample collection. Pregnant patients were recruited into a clinical research program sponsored by Illumina that complies with the International Conference on Harmonization of Good Clinical Practice. After informed consent, 20 mL of whole blood samples were collected from 40 pregnant women diagnosed with preeclampsia before 34 weeks of gestation with severe features that met the ACOG guideline definition (Table 6). Samples from 76 healthy pregnancies were also collected and matched with the preeclampsia group based on their gestational age. Three control samples developed full-term preeclampsia after blood collection and were excluded from data analysis. See Table 6 for detailed inclusion and exclusion criteria. The patient's clinical history, treatment, and birth outcome information were also recorded (Table 7).

[0266] Patients were recruited at eight different clinical sites, including the University of Texas Medical Branch (Galveston, Texas), Tufts Medical Center (Boston, MA), Columbia University Irving Medical Center (New York, NY), Winthrop University Hospital (Mineola, NY), Saint Peter's University Hospital (New Brunswick, NJ), Christiana Care (Newark, DE), Rutgers Robert Wood Johnson Medical School (New Brunswick, NJ), and NewYork-Presbyterian / Queens (New York, NY). The clinical protocol and informed consent form were approved by the institutional review board of each clinical site. See Table 8 for the distribution of patients across clinical sites.

[0267] PEARL Validation Cohort Study Design. Plasma samples obtained from the Preeclampsia and Growth Restriction Longitudinal Study (PEARL; NCT02379832) by Illumina will be used as an independent validation cohort. Plasma samples were obtained after study completion. PEARL samples were collected at the Centre Hospitalier de l'Universitaire du Québec (CHU de Québec) with the principal investigator, Emmanual Bujold, M.D. A cohort of 45 control pregnancies and 45 control pregnancies were enrolled in this study, and written informed consent was obtained from all patients. Only participants aged 18 years or older were eligible, and all pregnancies were singleton.

[0268] Pre-eclampsia group. Pre-eclampsia was defined according to the Society of Obstetricians and Gynecologists of Canada (SOGC) June 2014 criteria for pre-eclampsia, with a gestational age requirement of between 20 and 41 weeks. A blood sample was obtained once at diagnosis.

[0269] Control group. 45 pregnant women with normal pregnancy were recruited between 11 and 13 weeks of gestational age. Longitudinal blood draws were performed on each recruited patient at 4 time points throughout pregnancy to birth. The control women were divided into three subgroups, and subsequent follow-up blood draws were staggered to cover the entire gestational age range throughout pregnancy (Table 5).

[0270] The PEARL control samples were used for two purposes. 153 longitudinal samples from 45 individual women were used to monitor placental dynamics throughout pregnancy. In addition, control samples were selected for comparison with the preeclampsia cohort, which was matched for gestational age and used to validate the model.

[0271] Study sample processing. All samples collected prospectively from Illumina and PEARL samples were processed identically by investigators who were unaware of disease status. Two tubes of blood were collected from each patient in cell-free DNA BCT tubes (Streck) according to the manufacturer's instructions. Blood samples were stored and shipped overnight at room temperature and processed within 72 hours. The blood was centrifuged at 1,600×g for 20 minutes at room temperature, the plasma was transferred to a new tube, and centrifuged again at 16,000×g for 10 minutes to remove residual cells. The plasma was stored at -80°C until use. Circulating RNA was extracted from 4.5 mL of plasma using a circulating nucleic acid kit (Qiagen), followed by DNase I digestion (Thermofisher) according to the manufacturer's instructions.

[0272] cDNA synthesis and library preparation. Using Illumina TruSight Tumor 170 library preparation kit (Illumina) at 94 ° C, the circulating RNA was fragmented for 8 minutes, followed by random hexamer-induced cDNA synthesis. According to the TST170 tumor library preparation kit for RNA, Illumina sequencing library preparation was performed, and the following modifications were made to adapt to low RNA input. All reactions were reduced to 25% of the original volume, and the connection adapter was used at a dilution of 1 to 10. The library quality was assessed by Agilent Bioanalzyer 2100 (Agilent) using a high-sensitivity DNA analysis kit.

[0273] Whole exon enrichment. Sequencing libraries were quantified using the Quant-iT PicoGreen dsDNA kit (ThermoFisher Scientific), normalized to 200 ng input, and each enrichment reaction was pooled into 4 samples. Whole exon enrichment was performed according to the TruSeq RNA Access Library Preparation Guide (Illumina). Other blocking oligonucleotides lacking 5' biotin designed for hemoglobin genes HBA1, HBA2, and HBB were also included in the enrichment reaction to reduce the enrichment of these genes in the sequencing library. The final enriched library was quantified using the Quant-IT PicogreendsDNA kit (ThermoFisher Scientific), normalized, and pooled for paired-end 50×50 sequencing on the Illumina HiSeq 2000 platform, with a minimum depth of 40 million reads per sample.

[0274] Data analysis. Unless otherwise stated, all statistical tests are bilateral. When data are not normally distributed, nonparametric tests are used. Sequencing reads are mapped to the human reference genome (hg19) with high hat (v2.0.13), and transcript abundance is quantified with featureCounts (subread-1.4.6) relative to refGene coordinates (obtained on 10 / 27 / 2014). Tissue expression data are obtained from Body Atlas (CorrelationEngine, BaseSpace, Illumina, Inc) (Kupershmidt, et al., 2010, PLoS ONE [Public Library of Science Comprehensive] 5; 10.1371 / journal.pone.0013066). V genes expressing ≥ median expression 2 times in all tissues in placenta or any fetal tissue (brain, liver, lung and thyroid) are designated as the group. Subcellular localization is obtained from UniProt.

[0275] Differential expression analysis was performed in R (v3.4.2) using edgeR (v3.20.9) after excluding genes with CPM ≤ 0.5 in < 25% of the samples. The dataset was normalized by the TMM method, and differentially abundant genes were identified by glmTreat test for log fold change ≥ 1, followed by Bonferroni-Holm p-value correction. The same procedure was used for each jackknife iteration, using 90% of the samples in each group (selected by random sampling without replacement). After 1,000 jackknife iterations, one-sided 95% confidence intervals for gene-level p-values ​​were calculated with statsmodels (v0.8.0). Hierarchical clustering analysis was performed using squared Euclidean distance and average linkage.

[0276] AdaBoost was implemented in Python using machine learning (v0.19.1, sklearn.ensemble.AdaBoostClassifier). The best hyperparameter values ​​were determined via grid search (90 estimators and a learning rate of 1.6), and the performance was quantified using the Matthew correlation coefficient. The overall AdaBoost model development strategy is described in Figures 31A-31E The data set was standardized (sklearn.preprocessing.StandardScaler) before fitting the classifier (TMM-normalized log CPM values ​​of genes with CPM ≤ 0.5 in <25% of samples). The same scaler fitted to the training data was applied to the corresponding test data set; all 5 scalers used for the 5 training data sets were averaged for the final model. The decision function scores were used to construct the ROC curve and determine the sample classification.

[0277] RT-qPCR validation assay and analysis. C-RNA was isolated from 2 ml of plasma from 19 randomly selected pre-eclampsia (PE) and 19 matched control samples and converted to cDNA. The cDNA was preamplified for 16 cycles using TaqMan Preamp master Mix (Catalog 4488593) and diluted 10-fold to a final volume of 500 μL. For qPCR, the reaction mixture contained 5 μL of diluted pre-amplified cDNA, 10 μL of TaqMan gene expression master mix (Catalog No. 4369542), 1 μL of TaqMan probe, and 4 μL of water using the manufacturer's instructions. For each TaqMan probe (Table 9), three qPCR reactions were performed for each diluted cDNA sample, and the Cq value was determined using the Bio-Rad CFX Manager software. To determine the gene abundance of each target gene, the average Cq value (reference Cqavg) between the five reference gene probes was used to calculate ΔΔCq=2^-(target Cq-reference Cq avg To determine the fold change (PE / CTRL) for each probe, the ΔΔCq value for each sample was divided by the mean ΔΔCq value of the matched control group.

[0278] Test tube type study. In order to evaluate the effect of test tube type and overnight transportation on circulating RNA quality, blood was extracted from pregnant and non-pregnant women in the following test tube types: K2 EDTA (BD (Beckton Dickinson)), ACD (BD (Beckton Dickinson)), cell-free RNA BCT test tube (Streck) and 1 cell-free DNA BCT test tube (Streck). 8mL of blood was extracted in each test tube and transported overnight on ice packs (EDTA and ACD), or at room temperature (cell-free RNA and DNA BCT test tubes). All transported blood test tubes were processed into plasma within 24 hours after blood drawing. As a reference, 8mL of blood was also extracted in K2 EDTA test tubes and processed into plasma on site within 4 hours and transported on dry ice as plasma. All plasma processing and circulating RNA extraction were performed as described in the method section. 3mL of plasma was used for each condition to generate sequencing libraries, enriched using the Illumina (Illumina) protocol as described.

[0279] Reproducibility study. Plasma was obtained from 10 individuals and divided into 4mL, 1mL and 0.5mL volumes, and each volume was repeated 3 times. As previously mentioned, all samples were subjected to circulating RNA extraction (Qiagen circulating nucleic acid kit) and random-primed cDNA synthesis. For libraries input using 4.5mL plasma, sequencing libraries were generated using the TST170 tumor library preparation kit as described above. For 1mL and 0.5mL input, libraries were generated using the Accel-NGS 1S Plus DNA library kit (Swift Biosciences). As described above, all samples were subjected to full exon enrichment and sequencing.

[0280] discuss

[0281] This study focused on identifying differences in the prevalence of early-onset PE, supporting the ultimate goal of clinically actionable biomarker discovery. This required adapting analytical methods to account for the variability observed in the data. This variability stems from the substantial biological noise in C-RNA measurements as well as the phenotypic diversity of PE. C-RNA is inherently more variable than single tissue transcriptomics as it represents a combination of cell death, signaling, and gene expression in all organs. Furthermore, PE exhibits a wide range of maternal and fetal outcomes that may be associated with different underlying molecular etiologies. Although the excluded genes may have biological relevance to PE, they were not prevalent in the cohort. Interestingly, the excluded transcripts were elevated in specific women who may represent a molecular subset of PE. Larger cohorts will help elucidate whether C-RNA can describe PE subtypes, which is critical to understanding the diverse pathophysiology of this condition.

[0282] The most common set of transcripts was identified by AdaBoost. The success of this approach was highlighted by highly accurate classification of an independent early-onset PE cohort (PEARL). These samples were collected from different populations with significantly loose inclusion and exclusion criteria, including, for example, women with chronic hypertension, gestational diabetes, or Alport syndrome in the control group - none of whom were mistakenly diagnosed with PE. In contrast to hierarchical clustering, 17 of the 24 individuals in the late-onset PE cohort were correctly classified by the machine learning model of this example, which is surprising given that early-onset PE and late-onset PE are different conditions. The findings of this example suggest that there may be some commonly altered pathways in all PE.

[0283] In each assessment, C-RNA revealed changes in transcripts expressed by the placenta, fetus, and mother. One of the most significant trends observed in PE samples was an increase in the abundance of a large number of ECM remodeling and cell migration / invasion proteins (FAM107A, SLC9A3R2, TIMP4, ADAMTS1, PRG2, TIMP3, LEP, ADAMTS2, ZEB1, HSPA12B), accompanied by dysfunctional extravillous trophoblast infiltration and the remodeling of maternal blood vessels characteristic of this disease. The maternal side of premature PE is manifested by cardiovascular dysfunction, inflammation, and premature birth (PNMT, ZEB1, CRH), all of which show molecular signals of abnormal behavior in the data of this example.

[0284] Table 5: Gestational age distribution of the PEARL control cohort of 45 healthy pregnancies

[0285]

[0286] Table 6: Diagnostic criteria and inclusion / exclusion criteria for pre-eclampsia with severe features

[0287]

[0288]

[0289] Table 7: Study characteristics of the Illumina pre-eclampsia cohort

[0290]

[0291]

[0292] *Defined as birth weight < 10% of the male or female fetal population

[0293] Table 8: Distribution of patients at collection sites in medical centers

[0294]

[0295]

[0296] Table 9: Genes validated by TaqMan qPCR

[0297]

[0298]

[0299] Table 11: Study characteristics of the Illumina pre-eclampsia cohort

[0300]

[0301]

[0302] *Defined as birth weight < 10% of the male or female fetal population

[0303] The complete disclosure of all patents, patent applications, and publications cited herein, and electronically available materials (including, for example, nucleotide sequence submissions, such as GenBank and RefSeq, and amino acid sequence submissions, such as SwissProt, PIR, PRF, PDB, and translations of annotated coding regions from GenBank and RefSeq) is incorporated by reference in its entirety. Supplementary materials cited in publications (such as supplementary tables, supplementary figures, supplementary materials and methods, and / or supplementary experimental data) are likewise incorporated by reference in their entirety. In the event of any inconsistency between the disclosure of the present application and the disclosure of any document incorporated by reference, the disclosure of the present application shall prevail. The above detailed description and examples are given only for the sake of clear understanding. It should not be understood as unnecessary limitations. The present disclosure is not limited to the precise details shown and described, and obvious changes to those of ordinary skill in the art will be included in the present disclosure defined by the claims.

[0304] Unless otherwise indicated, all numbers used in the specification and claims indicating components, molecular weights, etc., should be understood as being modified in all cases by the term "about". Therefore, unless otherwise indicated to the contrary, the numerical parameters listed in the specification and claims are approximate values, which may vary depending on the desired properties sought to be obtained by the present invention. At a minimum, and without attempting to limit the application of the doctrine of equivalents to the scope of the present claims, each numerical parameter should at least be interpreted in accordance with the number of reported significant digits and by applying ordinary rounding techniques.

[0305] Although the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values ​​set forth in the specific examples are reported as precisely as possible. However, all numerical values ​​inherently contain a range necessarily resulting from the standard deviation found in their respective testing results.

[0306] All headings are intended for the convenience of the reader and should not be used to limit the meaning of the text that follows the heading unless so indicated.

Claims

1. A circulating RNA (C-RNA) molecule, or a probe capable of binding to and / or identifying the C-RNA molecule, or a primer for selectively amplifying the C-RNA molecule, for use in preparing a reagent for detecting pre-eclampsia in pregnant women, comprising: identifying a plurality of circulating RNA (C-RNA) molecules in a biological sample obtained from the pregnant woman; wherein the plurality of C-RNA molecules comprises a plurality of C-RNA molecules encoding at least a portion of all seven of ADAMTS2, ARRDC2, PAPPA2, LEP, CLEC4C, ARHGEF25 and VSIG4 proteins, which indicates pre-eclampsia in the pregnant woman.

2. Use of a circulating RNA (C-RNA) molecule, or a probe capable of binding to and / or identifying the C-RNA molecule, or a primer for selectively amplifying the C-RNA molecule, for preparing a reagent for detecting pre-eclampsia in pregnant women, comprising: obtaining a biological sample from the pregnant woman; purifying a population of circulating RNA (C-RNA) molecules from the biological sample; identifying a protein coding sequence encoded by the C-RNA molecule in the purified C-RNA molecule population; wherein the protein coding sequence encoded by the C-RNA molecule comprises a protein coding sequence encoding at least a portion of all seven ADAMTS2, ARRDC2, PAPPA2, LEP, CLEC4C, ARHGEF25 and VSIG4 proteins, which indicates pre-eclampsia in the pregnant woman.

3. The method of claim 1 or 2, wherein identifying the protein coding sequence encoded by the C-RNA molecule in the biological sample comprises hybridization, reverse transcriptase PCR, microarray chip analysis or sequencing.

4. The method of claim 1 or 2, wherein identifying the protein coding sequence encoded by the C-RNA molecule in the biological sample comprises sequencing.

5. The use of claim 4, wherein sequencing comprises massively parallel sequencing of clonally amplified molecules.

6. The use according to claim 4 or 5, wherein sequencing comprises RNA sequencing.

7. The use according to any one of claims 1 to 6, further comprising: removing intact cells from said biological sample; treating the biological sample with deoxyribonuclease (DNase) to remove cell-free DNA (cfDNA); synthesizing complementary DNA (cDNA) from C-RNA molecules in the biological sample; and / or enriching the cDNA sequence for protein-encoding DNA sequences by exon enrichment; The protein coding sequences encoded by the circulating RNA (C-RNA) molecules are then identified.

8. Use of a circulating RNA (C-RNA) molecule, or a probe capable of binding to and / or identifying the C-RNA molecule, or a primer for selectively amplifying the C-RNA molecule, for preparing a reagent for detecting pre-eclampsia in pregnant women, comprising: obtaining a biological sample from the pregnant woman; removing intact cells from said biological sample; treating the biological sample with deoxyribonuclease (DNase) to remove cell-free DNA (cfDNA); synthesizing complementary DNA (cDNA) from RNA molecules in the biological sample; enriching said cDNA sequence for protein-encoding DNA sequences (exon enrichment); Sequencing the obtained enriched cDNA sequence; as well as Identifying protein coding sequences encoded by the enriched C-RNA molecules; wherein the protein coding sequence encoded by the C-RNA molecule includes a protein coding sequence encoding at least a portion of all seven ADAMTS2, ARRDC2, PAPPA2, LEP, CLEC4C, ARHGEF25 and VSIG4 proteins, which indicates pre-eclampsia in the pregnant woman.

9. The use according to any one of claims 1 to 8, wherein the biological sample comprises plasma.

10. The use according to any one of claims 1 to 8, wherein the biological sample is obtained from a pregnant woman at less than 20 weeks of gestation.

11. The use according to any one of claims 1 to 8, wherein the biological sample is obtained from a pregnant woman at a gestational age of greater than 20 weeks.

12. The use according to any one of claims 1 to 8, wherein the sample is a blood sample, and before the blood sample is processed into plasma, the blood sample is collected, transported and / or stored in a test tube with cell and DNA stabilizing properties.

13. The use according to claim 12, wherein the test tube contains Streck Cell-Free DNA BCT ® Blood collection tubes.

14. The use of claim 9, wherein the biological sample is obtained from a pregnant woman at less than 20 weeks of gestation.

15. The use of claim 9, wherein the biological sample is obtained from a pregnant woman at a gestational age greater than 20 weeks.

16. The use according to any one of claims 1 to 8, wherein: ADAMTS2, ARRDC2, PAPPA2, LEP, ARHGEF25, and VSIG4 are increased relative to levels in gestational age-matched control pregnant women without pre-eclampsia; and / or CLEC4C was decreased relative to levels in gestational age-matched control pregnant women who did not suffer from pre-eclampsia.

17. The use according to any one of claims 1 to 8, wherein the biological sample is obtained from a pregnant woman at less than 16 weeks of gestation.

18. The method of claim 9, wherein the biological sample is obtained from a pregnant woman at less than 16 weeks of gestation.